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Lactobacillus reuteri, a ubiquitous inhabitant of the mammalian gastrointestinal (GI) 
tract has known health-promoting effects and various strains are commercially available 
as probiotics. Several probiosis mechanisms have been suggested in L. reuteri’s mode of 
action, but the mediators and factors involved are not well understood. This thesis 
examined the function of probiotics, particularly L. reuteri, in the GI tract by equipping 
L. reuteri ATCC PTA 6475 and R2LC with reporter genes (luminescence and 
fluorescence) and a mutant of strain 6475 was generated by inactivation of chaperon 
dnaK. Different in vitro and in vivo applications of fluorescent and luminescent strains 
were evaluated, and it was demonstrated that flow cytometry can be a powerful method 
for determination of plasmid persistence. Biophotonic imaging (BPI) enabled low doses 
(~1x105) of luminescent bacteria to be monitored in the GI tract and revealed retention 
of large numbers of bacteria in the stomach up to 3 hours post-gavage. The effect of four 
strains of L. reuteri (6475, R2LC, DSM 17938, 1563F) was examined in an epithelial 
infection model using IPEC-J2 cells induced by enterotoxigenic E. coli. By analysing 
transepithelial electrical resistance (TEER) and leakage of FITC-dextran, it was shown 
that L. reuteri pre-treatment prevented damage by ETEC to epithelial monolayer 
integrity. The strains also reduced expression of pro-inflammatory cytokines (TNFD and 
IL-6) and maintained expression of adherens junction (E-cadherin) and upregulated tight 
junction (ZO-1) proteins. 
To further explore the L. reuteri mode of action, five mutants were evaluated in DSS-
induced acute colitis and IPEC-J2 models. It was found that dnaK–, pduC–, cmbA–, 
amidase௅ and srtA– may not play major roles in the mechanisms by which 6475 maintains 
mucosal integrity and counteracts inflammation. However, mutants 6475 pduC࣓and 6475 
cmbA࣓ had a tendency to weaken the protective effect of 6475 in the colitis model. 
Studies on the effects of L. reuteri strains on mast cell activation and inflammatory 
response revealed no inhibition of degranulation mediated by IgE-antigen activation, but 
downregulated expression of the pro-inflammatory cytokines IL-6 and IL-13, 
irrespective of degranulation. Thus pre-treatment with L. reuteri strains can protect 
against intestinal barrier dysfunction and mucosal inflammation, partly through altering 
junctional complex proteins, mediators of immunity and mast cells.
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Abstract
To my family. 
It is not the strongest of the species that survive nor the most intelligent, but the 
one most responsive to the changes.  
Charles Darwin, 1809
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1.1 General background
The human body is constantly exposed to different types of microorganisms 
present in the environment. The first line of host defence in the early phase is 
provided by physical barriers such as skin and mucus in different parts of the 
human body. The inner wall of the intestine is a specialised barrier against food-
derived antigens and microbes. The human gastrointestinal (GI) tract is a 
complex and dynamic ecosystem harbouring trillions of microbes known as the 
microbiota. This master organ serves as a major regulator of human and animal 
health through digestion and defence and immunity. It is believed that the GI 
tract skilfully communicates with other organs in the human body and regulates 
their function. In fact, the intestine could be considered the largest immune 
organ, as it is highly involved in tolerance and immunity. The interaction of the 
mucosa with lumen content (i.e. food and microbiota) preliminarily defines the 
microbial community. A disturbance in the composition and function of the 
microbiota (dysbiosis) has been associated with hyperpermeability of the 
intestine (leaky gut) and, as a result, pathogenesis of many disorders and diseases 
such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), 
diabetes type I and many more.
The intestinal microbial community in humans is dominated by the phyla 
Firmicutes and Bacteroidetes. Lactobacillus species belong to the Firmicutes 
and are considered beneficial members of the GI tract. Several Lactobacillus
species have been shown to have beneficial effects on human and animal health, 
and are currently permitted for use as probiotics.  
Elie Metchnikoff (1845-1916) can be considered the father of the probiotic 
concept. Although, the term ‘probiotics’ was not introduced by him, he was the 
first to describe the benefits of administering sour milk containing “Bulgarian 
1 Introduction 
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Bacillus” (later described as Lactobacillus delbrueckii subsp. Bulgaricus). Use 
of probiotics was born when physicians started prescribing the sour milk diet for 
patients. The term probiotics, which was introduced by Lilley and Stillwell 
(1965), is nowadays part of our common vocabulary.  
Awareness of the importance of Lactobacillus has led to use of this 
microorganism in the food/feed industry and recently in the medical and 
healthcare fields. Lactobacillus reuteri is ubiquitously indigenous to the GI tract 
of mammals. Protection and restoration of the gut barrier and function by 
Lactobacillus reuteri has previously been reported in animal models and human 
clinical trials, but the exact mechanisms of their probiosis are not yet known. 
The possibilities of probiotic therapies have been assessed for promoting health 
and curing diseases in human and animals for several decades (Iannitti and 
Palmieri, 2010). Today, probiotics are available in food and dietary supplements 
(offered as capsules, tablets, powders or liquid suspensions) that each contain a 
specific type of probiotic bacteria or mixture of a few probiotic strains.    
This thesis investigated the probiotic mechanisms of action of L. reuteri. The 
thesis starts with an introductory part, providing a broad background to the 
physiology of the GI tract, gut immunity and defence, including mucosal barrier, 
probiotics and an overview of mechanisms of action of probiotics, with the focus 
on L. reuteri strains and their health benefits. Chapter 2 lists the aims of the 
work. The material and methods used to conduct these studies are then briefly 
described in (Chapter 3), followed by a summary of the results (Chapter 4) and 
a discussion (Chapter 5).
This thesis also presents a preliminary study on the interaction between mast 
cells and L. reuteri and the effect of probiotics on mast cell activation, which 
gives further knowledge regarding the L. reuteri-host immune response. The 
methods used to perform this study are described in detail in (Chapter 3) and 
the results and a discussion of the findings at the end of (Chapter 4) and 
(Chapter 5), respectively.
1.2 Gastrointestinal (GI) tract physiology and defence 
mechanisms 
1.2.1 The gastrointestinal (GI) tract
The gastrointestinal (GI) tract is a hollow tube that extends from mouth to anus. 
The small and large intestine are two main parts of the GI tract. The small 
intestine is divided into three different anatomical and physiological sections 
(duodenum, jejunum and ileum) and is the major site for the absorption of 
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nutrients, water and minerals (Volk and Lacy, 2017). In humans, the lower part 
of the GI tract is called the large intestine or colon. It is 90-150 cm long, is 
located immediately after the small intestine and consists of ascending, 
transverse and descending loops and the rectum, which ends with the anus. The 
large intestine is also involved in the absorption of water and electrolytes 
(Kararli, 1995, Mowat and Agace, 2014).   
1.2.2 The intestine wall
The wall of the GI tract has four basic layers: mucosa, muscularis mucosa, 
submucosa and serosa (Figure 1). The inner layer, the mucosa, has two main 
functions; secretion and absorption and being a selective barrier. Therefore, 
maintenance of the mucosal functions is extremely important. The mucosa in the 
small intestine is folded to form crypts and villi, which increase the area of the 
active epithelium and absorption, while villi are absent from the colon 
(Johansson et al., 2011a, Mowat and Agace, 2014). The intestinal epithelial cells 
(IEC) (enterocytes) of the mucosa are joined tightly with neighbouring cells by 
tight junctions and are covered by a mucus layer. 
Figure 1. The wall of the gastrointestinal tract and its four different layers: mucosa, muscularis 
mucosa, submucosa and serosa.

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1.2.3 Intestinal barriers 
The intestinal barrier and gut permeability 
The main function of the GI tract is the digestion and absorption of nutrients and 
electrolytes. However, it has another extremely important function; regulating 
the host-environment interaction through its barrier function. The disruption of 
the mucosal barrier leads to translocation of luminal antigens and gut microbes 
into the lower layers of the intestine.
Intestinal permeability is associated with the barrier function and is defined 
as “the facility with which enterocytes allow molecules to pass through by non-
mediated passive diffusion” (Travis and Menzies, 1992). This property of the 
intestinal mucosa is associated with passage of ions and molecules of low 
molecular weight across the gut wall. Two different pathways, paracellular and
transcellular pathways, are involved in molecular transport from the lumen to 
the lamina propria, and are facilitated by junctional complexes between 
neighbouring intestinal epithelial cells and transcytosis, respectively (Menard et 
al., 2010). The intestinal barrier function is maintained by a complex multilayer 
system and can be divided into outer physical and inner immunological barriers 
(Figure 2). Disruption of the intestinal barrier, followed by infusion of luminal 
antigens, induces the mucosal immune response and inflammation, which is 
known to be a cause of onset and development of many intestinal and systemic 
diseases (Lee, 2015). 

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Figure 2. The different layers of intestinal barrier: inner and outer mucus layers, a single layer of 
intestinal epithelial cells and an immune barrier in the lamina propria.
Outer physical barrier 
The intestinal barrier is a major line of defence between the body and the external 
environment, with a surface area of 300-400 m2 (Anderson et al., 2012). The 
outer physical barrier of the intestine is made up of a single layer of columnar 
epithelial cells covered by a mucus layer.
(i) Mucus layer 
The mucus layer has direct contact with food, microbes and antigens in the GI 
tract (Mowat and Agace, 2014). It is also considered to be a chemical barrier in 
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the intestine and has a thickness that varies from 10 to 100-200 m in different 
parts of the intestine (Lundquist and Artursson, 2016). The mucus is secreted by 
goblet cells and is mainly composed of mucins, which are glycosylated proteins 
and have an ability to filter molecules with a cut-off size of 600-800 Daltons. 
The mucin in the colon and small intestine is mainly MUC2 (Wang et al., 2005).
The mucus layer of the small intestine consists of one layer, while that in the 
large intestine has two layers (Johansson et al., 2011b, Antoni et al., 2014). The 
mucus layer in the small intestine is not continuous and is less well defined 
compared with the colon with its thick inner firmly adhering and outer loosely 
adhering mucus layers (DeSesso and Jacobson, 2001, Atuma et al., 2001). The 
loosely adhering mucus layer is a major habitat for commensal bacteria and the 
firmly adhering inner layer largely has a protective function against luminal 
bacteria (Johansson et al., 2011b, Johansson et al., 2008b, Dicksved et al., 2012). 
The loosely adhering layer is considered to be produced as a result of 
SURWHRO\WLFFOHDYDJHRI08&E\WKHSURWHRO\WLFHQ]\PHPHSULQȕ(Johansson 
et al., 2008a, Birchenough et al., 2015). The mucus layer is continuously 
renewed by the goblet cells, which decelerate penetration by microbes 
(Birchenough et al., 2015).  
(ii) Intestinal epithelial cells 
Around 80% of the intestinal epithelial cells (IEC) on the villi surface are 
columnar absorptive cells (i.e. enterocytes) (Van der Flier and Clevers, 2009).
In the crypts of the villi, there are stem cells that continually divide and 
differentiate into different cell types, including absorptive enterocytes, enteric 
endocrine cells, mucus-secreting goblet cells, Paneth cells that secrete 
antimicrobial peptides and microfold (M) cells that sample the antigens. Apart 
from Paneth cells, which remain in the crypts, the other cell types migrate up to 
the tips of the villi in order to replace the aged cells at the tips (DeSesso and 
Jacobson, 2001, Menard et al., 2010). Epithelial barrier unity and polarity are 
maintained by the junctional complexes. The duties of these junctions are 
enabling passage of small macromolecules, electrolytes and fluids, and 
inhibition of passage of large macromolecules through the barrier (Lee, 2015) .  
(iii) Cellular components of the mucosal barrier  
Junctional complexes are vital for cell-cell contact and can be divided into three 
different structures: tight junctions, adherens junctions and desmosomes (Zihni 
et al., 2016) (Figure 3).

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Figure 3. Schematic diagram of junctional complexes, showing the location of tight junctions (TJ), 
adherens junctions (AJ) and desmosomes in epithelial cells.
Epithelial tight junctions (TJs) are mainly responsible for regulating 
paracellular influx of different sizes of molecules between the epithelial cells. 
Tight junctions are multi-protein complexes, including both transmembrane and 
peripheral membrane proteins. They interact with the cytoplasmic cytoskeleton 
in the cytoplasm and interact with the neighbouring cells. The claudin family 
and zonula occludens are the most important transmembrane and peripheral 
membrane proteins, respectively, and have crucial roles in assembly of the 
junction barriers. Intracellular domains of the transmembrane proteins interact 
with intracellular scaffolding proteins, zonula occludens and actin cytoskeletons 
(Suzuki, 2013, Zihni et al., 2016). The tight junction barriers can be divided into 
the paracellular barrier, with selective permeability for both large and small 
molecules through different diffusion pathways, and the intramembrane barrier, 
which restricts the exchange between the apical and basolateral cell surfaces 
(Zihni et al., 2016). 
Adhesion junctions and desmosomes are involved in communication and 
adhesion between the cells that maintain cellular proximity. Adherens junctions 
are composed of a family of transmembrane proteins, cadherins including E-
cadherin and catenin, that contributes to development of the perijunctional 
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actomyosin ring (Suzuki, 2013). Desmosomes are hyper-adhesive proteins of 
intercellular junctions and are involved in cell-cell communication and bindings 
(Garrod and Chidgey, 2008).
Inner immunological barrier and defence in the GI tract 
(i) Response to antigenic bodies and microbes
When a pathogen crosses the physical barrier, it is exposed to the first line of 
immune defence, the innate immune system. This part of the immune system 
plays an essential role in the early recognition of pathogens (Mogensen, 2009)
and is mostly facilitated by antigen-presenting cells (APCs) and phagocytic cells 
(Iwasaki and Medzhitov, 2004). The host innate immune response is initiated 
upon recognition of conserved structures of microbes known as pathogen-
associated molecular patterns (PAMPs) (Van den Abbeele et al., 2011) or 
microorganism-associated molecular patterns (MAMPs) (Lin and Zhang, 2017) 
through pattern recognition receptors (PRRs), including the families of toll-like 
receptors (TLRs) and nude-like receptors (NLRs). Upon exposure to the 
pathogen, PAMPs are recognised by the PRRs present at the cell surface and 
pro-inflammatory and antimicrobial responses are activated via induction of a 
multitude of signal transduction pathways (Akira and Takeda, 2004).
Subsequently, gene expression is activated and numerous molecules, including 
cytokines, chemokines and cell adhesion molecules, are synthesised, which 
together organise the early and late phase infection, including induction of the 
adaptive immune response (Akira et al., 2006). Therefore, invading microbes 
that escape the innate defence encounter the second line of defence, an activated 
adaptive response.
The gut constitutes the largest immune organ of the body due to the presence 
of the gut-associated lymphatic tissue (GALT). The GALT is divided into 
organised tissues consisting of Peyer’s patches, mesenteric lymph nodes 
(MLNs) and smaller isolated lymphoid follicles that are involved in the 
induction phase of the immune response. The Peyer’s patches are lymphoid 
nodules in the submucosa of the small intestine that are covered by a follicle-
associated epithelium (FAE) and characterised by the presence of M cells that 
are directly involved in antigen sampling from the lumen and delivering it to 
antigen-presenting cells such as dendritic cells (DC) (Geboes, 2003, Ohno, 
2016). The processed antigen is introduced to immune cells by antigen-
presenting cells and antigen-specific effector cells that migrate to the mesenteric 
lymph nodes (MLN) and, as a result, further mucosal immunity or tolerance is 
full-fledged. Furthermore, based on the type of stimulus, naive B cells can 
undergo immunoglobulin class switching from expression of IgM to IgA 
(Mowat, 2003). 
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Antigen translocation is controlled by IgA. The IgA-antigen complex can 
also be recognised by IgA receptors on the M cells. In the lamina propria, 
antigen-presenting dendritic cells receive the antigen, which is then processed 
and presented to T cells. As a result, T cells are primed and differentiated into 
different T cell types (Th/Treg) based on the antigenic immune-stimulation and 
expressed cytokines from APC and other cells (Anderson et al., 2012).   
(ii) Immune mediators
Cytokines are small peptides or proteins that are produced by various cell 
populations such as immune and epithelial cells, and are involved in cell 
signalling. Cytokines may act on the secreting cell (autocrine action), on nearby 
cells (paracrine action) or on distant cells (endocrine action) (Zhang and An, 
2007). They play a central role in coordinating maturation of the immune system 
and regulating responses to antigens, but also by activating several functions of 
epithelial cells, which in response produce many cytokines and chemokines that 
further regulate the immune responses /XQQH\9LOþHN6FKHOOHUHW
al., 2011).  
(iii) Some examples of cytokines
TNF-Į is a pro-inflammatory cytokine and a master regulator of pro- and anti-
inflammatory cytokines with a diverse range of biological activities. This 
multifunctional cytokine affects lipid metabolism, coagulation, insulin 
resistance and endothelial (Stenvinkel et al., 2005) and epithelial dysfunction 
(Al-Sadi et al., 2009). TNF-Į LV SURGXFHG E\ YDULRXV FHOO W\SHV LQFOXGLQJ
monocytes, macrophages, B cells, T cells, and NK cells, in response to different 
stimuli such as bacterial toxins and inflammatory products (Tracey and Cerami, 
1993). 
IL-13 is a multifunctional cytokine (Minty et al., 1993) and is produced by, 
and affects, many cell types such as macrophages, mast cells, epithelial cells and 
fibroblasts (Wynn, 2003). It is produced in high levels by CD4+ Th2 cells, and 
in lower levels by Th0 and CD8+ T cells (de Waal Malefyt et al., 1995). IL-13 
is functionally associated with IL-4 and, although the cytokines share several 
functions, IL-13 appears to play a more essential role than IL-4 (Wynn, 2003).
Several effector functions are known for IL-13, including regulation of 
gastrointestinal parasite expulsion, airway hyperresponsiveness (AHR), allergic 
inflammation, mastocytosis, IgE and antibody production, goblet cell 
hyperplasia and mucus production, tissue remodelling and fibrosis (Wynn, 
2003). 
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IL-6 is a cytokine with both pro- and anti-inflammatory properties (Scheller 
et al., 2011) and is produced by various types of immune cells, including 
fibroblasts, adipocytes, mesothelial, monocytes and lymphocytes. IL-6 is often 
produced in response to stimuli, such as bacterial endotoxins, oxidative stress 
physical exercise, TNF-ĮDQG,/-ȕ(Stenvinkel et al., 2005).   
(iv) Mast cells
Mast cells are a versatile cell type and are part of the innate immunity (Meurer 
et al., 2016). They are highly granulated leukocytes that are derived from 
haematopoietic stem cells. Following migration from bone marrow, they enter 
the blood circulation as progenitor cells and undergo final differentiation and 
maturation. They are usually present in high numbers in vascular tissues that 
encounter the external environment, such as skin, intestine and airways. Upon 
exposure and early recognition of antigens, mast cells are activated and undergo 
degranulation, which leads to the release of a variety of pre-formed mediators 
such as histamine, the proteases tryptase and chymase, and large numbers of 
cytokines and chemokines (Abraham and St John, 2010, Dawicki and Marshall, 
2007). 
Mast cells are able to interact directly with PAMPs through expression of 
TLRs. Mast cells are known for their involvement in allergies and the best 
studied mechanism for the activation and degranulation of mast cells is through 
stimulation of high-DIILQLW\ ,J( UHFHSWRU)Fİ5, (Abraham and St John, 2010, 
Gilfillan and Tkaczyk, 2006). However, degranulation and activation can also 
occur in response to other external stimuli such as complements, neuropeptides 
and certain toxins (Wernersson and Pejler, 2014).  
An allergic reaction is established when APCs encounter an allergen and as 
a result B cells produce antigen-specific immunoglobulin E (IgE). The IgE 
PROHFXOHVELQGWR)İ5,RQWKHVXUIDFHVRIPDVWFHOOVDQGDIWHUUH-encountering 
the same allergen, cross-OLQNLQJRI)İ5,-associated IgE molecules by the antigen 
leads to activation of WKH PDVW FHOO )İ5, UHFHSWRU FRQVLVW RI WKUHH GLIIHUHQW
VXEXQLWVĮ-ȕ- DQGWZRȖ-FKDLQVWKDWFDQIRUPDWULPHULFĮȖRUWHWUDPHULFĮȕȖ
VWUXFWXUH RQ WKH FHOO VXUIDFHV 7KH Į-chain possesses high affinity for the Fc 
UHJLRQZKHUHDVWKHȕ- DQGȖ-chains are involved in signal transduction through 
immunoreceptor tyrosine-based activation motifs (ITAMs). Phosphorylation of 
the ITAMs by the Lyn protein leads to activation of spleen tyrosine kinase (Syk), 
which phosphorylates several signalling molecules, leading to degranulation 
(Garman et al., 2000, Turner and Kinet, 1999). 
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1.3 Microbiota of the GI tract and inflammatory bowel 
disease
1.3.1 The gut microbiota
The complex microbial community in the GI tract, which is known as the gut 
microbiota, consists of bacteria, fungi, archaea and viruses (Marchesi et al., 
2016). A recent investigation estimated the number of bacterial cells in the gut 
microbiota to be higher than 1013, which is 10-fold greater than the total number 
of human cells (Sender et al., 2016).  
The gut contains more than 1000 species, including eukarya (~100), archaea 
(~10) and bacteria (~1000) 5DMLOLü-6WRMDQRYLüDQGGH9RV. The colon 
contains the largest population of microorganisms in the GI tract, 1011 bacteria 
per gram. The stomach and the upper part of the small intestine contain 103 to 
104 bacteria per g and the lower small intestine 108 bacteria per g (Sender et al., 
2016). The most diverse and abundant bacteria belong to the four phyla
Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria 5DMLOLü-
6WRMDQRYLü DQG GH 9RV . Degradation of complex plant-derived 
polysaccharides and fermentation of carbohydrates are the main activities of the 
gut microbiota. The microbiota is known for its beneficial effect on the host and 
is considered to be an intestinal barrier that has a constructive impact on 
epithelial proliferation, survival and metabolism (Neish, 2009). In addition, as a 
result of fermentation of carbohydrates, the microbiota produces metabolites like 
short-chain fatty acids (SCFA), including acetate, propionate and butyrate (Kien, 
1996, Marchesi et al., 2016) that affect intestinal physiology and immune 
functions (Maynard et al., 2012, Canani et al., 2011). Butyrate is considered to 
be the most important SCFA for intestinal epithelial cell proliferation and 
differentiation, villi development, mucin production, intestinal motility, defence 
mechanism and barrier function of the gut (Guilloteau et al., 2010, Hamer et al., 
2008, Havenaar, 2011). The microbiota of the GI tract also enables its role of 
regulating the microbial community through limiting pathogen colonisation by 
competing for adhesion sites, increasing mucin production, producing 
antimicrobial compounds and optimising the composition of the microbiota 
(Neish, 2009).  
A healthy intestinal microbiota maintains intestinal immune homeostasis. 
Changes in microbial composition, function or local distribution are termed 
dysbiosis (DeGruttola et al., 2016). Dysbiosis can occur as a result of several 
factors, such as infection, ingestion of antibiotics and a poor diet (Budden et al., 
2017, Delzenne et al., 2011). Dysbiosis can lead to several intestinal and 
systemic diseases and disorders (DeGruttola et al., 2016), such as inflammatory 
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bowel disease (Manichanh et al., 2006, Peterson et al., 2008),  type 2 diabetes 
(Karlsson et al., 2013) and obesity (Turnbaugh et al., 2006, Ley et al., 2006).  
1.3.2 Inflammatory bowel disease (IBD)
Intestinal barrier dysfunction has been implicated in the pathophysiology of 
many intestinal diseases, such as inflammatory bowel disease (IBD), irritable 
bowel syndrome (IBS), coeliac disease and many more (Konig et al., 2016, 
Peterson et al., 2008).
Inflammatory bowel disease is a group of chronic relapsing disorders of the 
GI tract that includes ulcerative colitis (UC) and Crohn’s disease (CD). 
Inflammatory bowel disease is common in developed countries and the 
prevalence of the disease is 1 out of 200 individuals in the northern European 
countries (Gismera and Aladren, 2008). Ulcerative colitis is usually superficial, 
starts from the rectum and spreads proximally toward the colon. Crohn’s disease 
causes segmental transmural inflammation that can affect the entire GI tract, 
although the lower part of the ileum and proximal colon are the most affected 
sites (Geboes, 2003). 
The exact aetiology and pathogenesis of IBD is currently unknown, but 
several studies have shown strong evidence of a contribution of dysregulated 
immune responses, especially overly aggressive cell-mediated immunity to, in 
particular, the intestinal microbiota in genetically susceptible individuals 
suffering from a gut barrier dysfunction (Sartor, 2006a, Konig et al., 2016).  
The microbiota of IBD patients has been shown to differ from that of healthy 
individuals. It is not known whether the changes in the microbiota are the cause 
or consequence of the inflammation, but a balance between the microbiota and 
immune response seems to be a prerequisite for a healthy intestinal barrier 
(Vindigni et al., 2016). 
Strong support for involvement of the intestinal microbiota in IBD is 
provided by reports of therapeutic effects of antibiotics on dampening the flare-
up of the disease and an effect of probiotics that can counteract the symptoms of 
intestinal damage and inflammation, and ameliorate IBD (Gionchetti et al., 
2003, Sutherland et al., 1991, Oliva et al., 2012). In addition, data from a study 
using a mice model have revealed that presence of bacteria in the GI tract is 
required to initiate IBD, since IL-10-deficient mice developed colitis when 
colonised by enteric bacteria, but not under germ-free conditions (Hoffmann et 
al., 2011). Furthermore, genetic studies in humans and mice have shown that 
specific genetic variants of PRRs, which are involved in host-microbe 
interactions, have implications for the development of IBD (Inohara et al., 2003, 
Hisamatsu et al., 2003, De Jager et al., 2007, Fukata and Arditi, 2013). An 
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important aspect in the pathogenesis of IBD is dysregulation of the immune 
response to commensal bacteria in the intestine and it has been shown that 
establishment of Th1/Th2 and Th17/Treg cell imbalances is implicated in the 
pathogenesis of IBD (Sun et al., 2015).  
1.4 Probiotics 
1.4.1 Introduction to probiotics
Health-promoting benefits of consumption of microorganisms, especially lactic 
acid bacteria (LAB), a group of Gram-positive bacteria that are commonly used 
in food fermentation, have been known for many years. In 1965, the term 
‘probiotic’ was used by Lilly and Stillwell to describe substances produced by 
protozoa that could stimulate the growth of other organisms (Kaur et al., 2002). 
In 2001, probiotics were defined by the World Health Organization (WHO) as 
“live microorganisms which, when administered in adequate amounts, confer a 
health benefit on the host” (FAO, 2001). Probiotics comprise both bacteria and 
yeasts and the most commonly used probiotic bacteria belong to Lactobacillus
and Bifidobacterium.  
1.4.2 Selection criteria for probiotics
Selection criteria for a probiotic may include: 1) Stability of phenotype and 
genotype; 2) proven functional properties of the probiotic strain compared with 
the original isolate (Forssten et al., 2011, Ouwehand and Lahtinen, 2008); 3) 
acid and bile resistance, and survival and growth during gastrointestinal transit 
(Dunne et al., 2001); probiotics do not always need to colonise the intestinal tract 
to exert their effects (Ohland and MacNaughton, 2010), but they need to persist 
and be alive; 4) excluding or reducing pathogenic adherence; 5) capable of 
producing acids, hydrogen peroxide and bacteriocins antagonistic to pathogen 
growth (Kaur et al., 2002); 6) not having any transferable antibiotic resistance 
(Panel, 2012); 7) being safe, non-pathogenic, non-allergenic, non-
mutagenic/carcinogenic and capable of being tolerated by the immune system 
and not provoking immunity (Desai, 2008)  
1.4.3 Mechanism of action of probiotics 
Evidence-based analyses of data from human clinical trials have shown the 
clinical potential of probiotics against diseases and disorders (Indrio et al., 2014, 
Oliva et al., 2012, Harata et al., 2016). Mechanisms of probiotic action are 
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versatile and their beneficial effects are not a reflection of a single mechanism. 
Differences in mechanism not only exist among species, but may also exist 
between strains within the same species. The beneficial impact of probiotics 
often shows a discrepancy in results from experimental and clinical trials (Gou 
et al., 2014, Kristensen et al., 2016, Farnworth, 2008, Boyle et al., 2009, Huang 
and Huang, 2016, Sanders et al., 2013). This could be explained by differences 
in the models and techniques, types of probiotics and in in vivo studies, because 
of complexity of the signalling network in the GI tract, including probiotics-host 
and probiotics-intestinal microbiota interactions and treatment strategies. In 
addition, communication with the host is not restricted to the intestine, but 
extends to distant locations and the complicated network of the gut-organ axis.  
Probiotics may exhibit their health-promoting benefit through three main 
modes of action: competitive exclusion, improvement of barrier function and 
immune modulation.
Competitive exclusion along the epithelium 
Several studies have shown adhesion of probiotics to the intestinal mucosa in 
vitro (Boudeau et al., 2003, Resta-Lenert and Barrett, 2003, He et al., 2001) and 
in vivo (Valeur et al., 2004). It has been claimed that this adhesion of probiotics 
to the intestinal mucosa limits nutrient availability to other bacteria and restricts 
pathogen access to the epithelium (O'Hara and Shanahan, 2007). The adhesion 
of probiotics is mediated by several adhesion factors (Buck et al., 2005, van 
Pijkeren et al., 2006). The attachment of probiotics to the intestinal mucosa is 
mainly mediated by proteins. Some examples of adhesion proteins are mucus-
binding protein (MUB) produced by Lactobacillus reuteri (Roos and Jonsson, 
2002, Buck et al., 2005), and CmbA (cell- and mucus-binding protein A), which 
is reported to mediate the binding of L. reuteri to the mucus (Jensen et al., 2014).
Furthermore, probiotics may induce expression of mucins and subsequent 
thickening of the mucous layer that covers the intestinal mucosa (Ahl et al., 
2016, Caballero-Franco et al., 2007), which as a result may inhibit invasion by 
pathogens (Mack et al., 1999, Mack et al., 2003, Mattar et al., 2002). In addition, 
probiotic bacteria can modify the composition of the lumen microenvironment 
and inhibit pathogen growth through the production and/or release of a variety 
of antimicrobial factors. These antimicrobial factors include bacteriocins, 
hydrogen peroxide, nitric oxide, lactic and acetic acids and de-conjugated bile 
acids (Oelschlaeger, 2010b). 
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Enhancement of epithelial barrier function 
The intestinal barrier is the major defence mechanism of the host against the 
surrounding environment and disruption of the barrier causes penetration by 
bacterial and food antigens, which induce inflammatory responses (Sartor, 
2006b). The mechanisms by which probiotics enhance intestinal barrier function 
are not fully understood. Studies using animal and cell culture models have 
shown that probiotics can upregulate genes of the tight junction complex, for 
example E-FDGKHULQDQGȕ-catenin (Anderson et al., 2010). Other studies have 
indicated that probiotics may initiate repair of the intestinal barrier function after 
damage through upregulation and redistribution of tight junction proteins ZO-2, 
ZO-1 and occludin (Zyrek et al., 2007, Yang et al., 2015b, Ahl et al., 2016). It 
has also been shown that probiotics can prevent pro-inflammatory cytokine-
induced epithelial damage (Sartor, 2006b, Oliva et al., 2012, Kumar et al., 2017).
Furthermore, probiotic bacteria can prevent apoptosis in epithelial cells 
through regulation of both anti- and pro-apoptotic signalling pathways (Yan and 
Polk, 2002). Probiotics also induce mucus production in order to improve barrier 
function (Gaudier et al., 2005, Ahl et al., 2016).  
Recently, a systematic literature review of human trials studying the effect of 
probiotic products on the intestinal barrier was performed (van Hemert et al.,
2013). This review, of 29 published papers, found that the target patients, 
probiotic features and methods of measuring barrier function varied 
considerably. In approximately half of the studies reviewed, probiotics had 
positive effects and different markers of intestinal integrity such as zonulin, 
intestinal fatty acid-binding protein (IFABP), C-reactive protein (CRP), TNF-Į
Į-antitrypsin, lactulose/mannitol (L/M) test were assessed. It was concluded that 
the dosage, duration, bacterial strain and choice of marker for measuring 
intestinal integrity are important for future studies.   
Immune modulation
It is well known that bacteria can influence the host immune system by their 
metabolites, cell wall components and DNA. They have the ability to interact
with the intestinal epithelium, antigen-presenting cells like DCs and 
macrophages, and lymphocytes (Oelschlaeger, 2010a). The normal microbiota 
and possibly some probiotics create a tolerance state mediated by TLR7 and 
TLR3 on dendritic cells. However, the anti-inflammatory effects of probiotics 
may be mediated through the action of TLR9 signalling (Gomez-Llorente et al., 
2010, Bermudez-Brito et al., 2012).  
The signals from the microbiota are necessary for normal mucosal and 
immune development (Fukata et al., 2005, Rakoff-Nahoum et al., 2004). The 
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interaction is facilitated by PRRs (e.g. TLR) expressed on cells like enterocytes, 
dendritic cells and M cells (O'Hara and Shanahan, 2006), and initiates activation 
of signalling cascades of transcription of pro-inflammatory factors in 
immunosensory cells. TLRs play a crucial role in analysis of the 
microenvironment, which leads to discrimination between pathogens and the 
normal microbiota, while DCs can directly sample bacteria and prime the T cells, 
resulting in balancing of the T helper (Th) and regulatory T cell responses in the 
mucosa.  
It has been shown that the modulation of DC maturation and cytokine 
expression is not the same for all probiotic strains (Christensen et al., 2002, Hart 
et al., 2004). It is also known that DCs from different lymphoid tissues exhibit 
different cytokine responses to probiotic and pathogenic bacteria (O’Mahony et 
al., 2006). Data from studies on animal models of diseases indicate that the 
therapeutic effects of probiotics could be mediated through downregulation of 
the pro-LQIODPPDWRU\F\WRNLQHV71)ĮDQG,1)ȖDQGHQKDQFHPHQWRIUHJXODWRU\
cytokines, such as TGF-ȕ(McCarthy et al., 2003, Sheil et al., 2006, Madsen et 
al., 2001, Mohamadzadeh et al., 2005). Some Lactobacillus species, e.g. strains 
of L. casei and L. reuteri, adjust the immune response toward a tolerance state 
by activating the DCs to initiate the development of regulatory T cells with high 
expression of IL-10 and suppressing the proliferation of other effector T cells 
(Mohamadzadeh et al., 2005, Smits et al., 2005). Apart from modulation of T 
cell-mediated responses, probiotics have also been shown to enhance innate and 
humoral immune responses such as increased proportion and activity of 
phagocytic and natural killer cells, as well as levels of IgA in clinical trials 
(Olivares et al., 2010, Fang et al., 2000, Sheih et al., 2001, Rautava et al., 2006).
1.4.4 Health benefits of probiotics
Probiotic therapies have been evaluated for improvement of health and for 
curing diseases in human and animals for several decades (Iannitti and Palmieri, 
2010). Evidence-based analyses of data from human trials and animal models 
have shown the clinical potential of probiotics against many diseases and 
disorders (Indrio et al., 2014, Oliva et al., 2012, Harata et al., 2016).  
Some recent studies on the beneficial effect of probiotics have shown that 
some strains of probiotics can suppress diarrhoea caused by antibiotic treatment 
(Ruszczynski et al., 2008, Guarino et al., 2009) and Clostridium difficile
(Plummer et al., 2010); improve lipid profiles and lower serum cholesterol (LDL 
and HDL levels) (Harata et al., 2016) subsequently reduce the risk of 
hypertension (Lye et al., 2009); reduce lactose intolerance (Vonk et al., 2012),
and treat and prevent the recurrence of urogenital infections (Zuccotti et al., 
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2008, Czaja et al., 2007). Probiotics can also have beneficial effects on 
atopic/allergic diseases (de LeBlanc et al., 2007), rheumatoid arthritis (Mandel 
et al., 2010), postoperative complications (Nomura et al., 2006), IBS (O’Mahony 
et al., 2005, Kajander et al., 2008) and IBD (Mikov et al., 2014).  
1.5 Lactobacillus reuteri
Lactobacillus reuteri is a rod-shaped Gram-positive bacteria belonging to the 
genus Lactobacillus, which is the largest genus included in the LAB (Shahani 
and Ayebo, 1980). Lactobacillus reuteri was first described as a species in 1980 
and was previously regarded as Lactobacillus fermentum biotype II (Kandler et 
al., 1980). It can colonise the digestive tract of humans and other mammals and 
birds (Casas and Dobrogosz, 2000), but is predominantly found in the gut of 
rodents, pigs and poultry (Walter et al., 2011). It has also been isolated from the 
human mammary duct (milk) and genital tract (discharge) (Abrahamsson et al., 
2009, Reuter, 2001). Lactobacillus reuteri has been detected in only 10% of 
individuals (Valeur et al., 2004), but the proportion can vary depending on diet 
and population. For instance, a study in Papua New Guinea found 100% 
prevalence in that population (Martínez et al.). Analysis of faeces from healthy 
humans has indicated that the Lactobacillus genus accounts for less than 2% of 
total faecal bacteria (Sghir et al., 2000).  
1.5.1 Importance of probiotic characteristics of L. reuteri
There are important characteristics of L. reuteri that make several strains of this 
species interesting as potential probiotics.
Lactobacillus reuteri has been successfully administered orally and has been 
shown to be able to tolerate and survive the acidic conditions of the GI tract and 
persist in the presence of bile salts in the small intestine, where its strong
adherence to the mucus layer and intestinal epithelial cells has been 
demonstrated by several in vitro studies (Liu et al., 2014, Jensen et al., 2014, 
Walsham et al., 2016). This might be a requirement for the suppressive effect on 
pathogens seen in clinical trials (Savino et al., 2015).  
Other important probiotic characteristics of L. reuteri are production of 
bioactive metabolites and compounds. It has been shown that strains of L. reuteri
convert a dietary component, L-histidine, into histamine, which exerts anti-
inflammatory effects (Thomas et al., 2012). Bacterial histamine downregulates 
expression of TNF-D via activation of the histamine receptor H2 (Thomas et al., 
2012, Vannier et al., 1991).  
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Lactobacillus reuteri strains produce anti-microbial substances such as 
reuterin or reutericyclin. Reutericyclin is a cyclical tetramic acid and antibiotic 
produced by only some strains of L. reuteri (Holtzel et al., 2000). This metabolite 
disturbs the membrane of Gram-positive bacteria (Cherian et al., 2014) such as 
Clostridium difficile (Hurdle et al., 2011) and methicillin-resistant 
Staphylococcus aureus (MRSA) (Hurdle et al., 2009), but not of Gram-negative 
bacteria and yeasts (Ganzle et al., 2000). Reuterin (3-hydroxypropionaldehyde) 
is another anti-microbial molecule that induces oxidative stress in microbes 
(Chung et al., 1989). Reuterin is formed during anaerobic growth as a result of 
glycerol dehydration. Reduction of reuterin to 1, 3-propanediol regenerates 
NAD+ from NADH, contributing to better growth (Schaefer et al., 2010, Chung 
et al., 1989). 
It is known that not all L. reuteri strains are able to produce reuterin and that 
the level of reuterin production varies from one strain to another. For example, 
strains ATCC PTA 6475 and ATCC PTA 5289 produce lower levels than strains 
ATCC 55730 and CF48-3A (Jones and Versalovic, 2009). 
Vitamin B12 is another important metabolite, production of which is linked 
to the capacity to convert glycerol to reuterin. The genes required for B12 
synthesis have been identified in strains ATCC PTA 6475 (Santos et al., 2011)
and JCM 1112 (Santos et al., 2011, Morita et al., 2008). However, the only report 
of B12 production by L. reuteri has been identified as pseudo vitamin B12 
(Santos et al., 2007) and is produced by L. reuteri CRL 1098 (Santos et al., 2008, 
Taranto et al., 2003). 
1.5.2 Mode of action of L. reuteri and intestinal health benefits 
Lactobacillus reuteri has been shown to have positive effects on gastrointestinal 
barrier functions and the gut immune response, but the mechanism of action is 
not well known. However, it appears that L. reuteri exerts its beneficial effects 
through similar mechanisms as described for other probiotics including:  
1. Regulating and re-directing the immune response toward an anti-
inflammatory state and tolerance, through activation of Treg, upregulation of 
anti-inflammatory cytokines and downregulation of pro-inflammatory 
cytokines (Oliva et al., 2012, Lin et al., 2008b, Ahl et al., 2016, Liu et al., 
2013).  
2. Improvement of mucosal barrier and permeability through upregulating tight 
junction proteins, increasing the thickness of the mucus layer (Ahl et al., 
2016), upregulating defensins (Mackos et al., 2013) and regulating immune 
responses leading to tightening of the junctions between the cells, in 
particular apical junction complex (Yang et al., 2015b). 
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3. Exclusion of the pathogens by competing for adherence to the mucosa  and 
mucus layer, as shown by several in vitro studies (Walsham et al., 2016, De 
Weirdt et al., 2012) and in an infant clinical trial (Savino et al., 2015). 
4. Re-modelling and correction of the microbiota in humans and animals with 
dysbiosis, as reported recently in several studies (McFarland, 2014, Marin et 
al., 2017, Buffington et al., 2016). In two animal studies, remodelling of 
microbiota by L. reuteri led to a decrease in multi-organ inflammation in 
scurfy mice (He et al., 2017) and correction of the oxytocin levels and 
subsequent defective social behaviour associated with neurodevelopmental 
disorders in offspring caused by a maternal high-fat diet during pregnancy 
(Buffington et al., 2016). In a recent study in a chronically stressed mice 
model, alteration of microbiota composition in particular reduced 
Lactobacillus and increased circulating kynurenine levels (Marin et al., 
2017). It proved possible to re-establish the intestinal Lactobacillus levels by 
administering L. reuteri, which was sufficient to improve the metabolic shifts 
and despair behaviour in the mice model (Marin et al., 2017). 
1.5.3 Some recent preclinical and clinical effects of L. reuteri on the gut
Preclinical studies
Several studies using animal models and cell cultures have shown an anti-
inflammatory effect of L. reuteri (Thomas et al., 2012, Lin et al., 2008b, Jones 
et al., 2011, Thomas et al., 2016, Ahl et al., 2016). It has also been shown that 
oral pre-treatment with a cocktail of L. reuteri strains prevents onset of colitis in 
rats by downregulation of P-selectin and decreasing Crohn’s disease  leukocyte- 
and platelet-endothelial cell interactions (Schreiber et al., 2009). Another study 
using the same cocktail of L. reuteri strains (R2LC, JCM 5869, ATCC PTA 4659 
and ATCC 55730) demonstrated that L. reuteri does not improve the disruption 
of the mucus barrier caused by dextran sulphate sodium (DSS), but can reduce 
the DSS-associated bacterial translocation to mesenteric lymph nodes (Dicksved 
et al., 2012). A study Crohn’s disease using L. reuteri R2LC has also 
demonstrated that intracolonic administration prevents the development of 
acetic acid-induced colitis in rats and normalise Crohn’s disease the 
myeloperoxidase (MPO) activity and mucosal permeability (Fabia et al., 1993).
Moreover, it has been shown that oral administration of L. reuteri I5007 in 
newborn piglets improves mucosal integrity and upregulates expression of the 
apical junction proteins claudin-1, occludin and zonula occluden-1 (ZO-1) 
(Yang et al., 2015b).  
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In an in vitro study using the IPEC-J2 cell line, it was shown that pre-
treatment with a L. reuteri strain isolated from porcine gut prevented disruption 
of the mucosal integrity caused by enterotoxigenic Escherichia coli (ETEC) 
through increasing expression of the tight junction protein ZO-1 and heat shock 
protein HSP27 (Liu et al., 2015). In an in vitro infection model, L. reuteri I5007 
protected the mucosal barrier function against lipopolysaccharide (LPS) via 
maintenance of the expression of TNF-ĮDQG,/-6 and TJ proteins (Yang et al., 
2015b). 
A study on children with Crohn’s disease has demonstrated that L. reuteri
strain ATCC PTA 6475 can suppress TNF production by lipopolysaccharide-
activated monocytes and primary monocyte-derived macrophages and that this 
is achieved by blockage of activation of MAP kinase-regulated c-Jun and the 
transcription factor and AP-1 (Lin et al., 2008a). 
Clinical studies
Several human clinical trials have demonstrated the beneficial effects of L. 
reuteri, especially in infants and children. Lactobacillus reuteri has been proven 
to be an efficient probiotic. In treatment of infantile colic, ingestion of L. reuteri
strains DSM 17938 and ATCC 55730 has been proven to be better than a placebo 
in reducing crying (Savino et al., 2010, Savino et al., 2007, Indrio et al., 2014).
Oral administration of L. reuteri DSM 17938 appears to benefit gastrointestinal 
motility in infants, resulting in less overall regurgitation (37%) and improving 
bowel frequency (16%) (Indrio et al., 2014). 
In a preliminary case-control study, treatment of infants with L. reuteri DSM 
17938 decreased colonisation by EPEC (Savino et al., 2015). Lactobacillus 
reuteri DSM 17938 has also been shown to effectively reduce the duration of 
acute diarrhoea in children (Francavilla et al., 2012, Dinleyici and Vandenplas, 
2014). 
In a study on necrotising enterocolitis in newborn infants, Lactobacillus 
reuteri strains ATCC PTA 4659 and DSM17938 increased the survival rate and 
decreased the incidence and severity of the disease (Liu et al., 2012). 
The only published study on effects on IBD shows that rectal infusion of L. 
reuteri in children with active distal ulcerative colitis enhances the anti-
inflammatory cytokine IL-10, downregulates the pro-inflammatory cytokines 
IL-ȕ71)ĮDQG,/-8, and improves mucosal inflammation (Oliva et al., 2012).
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In recent years, research on the benefits of probiotics has grown rapidly and, as 
a result, the use of probiotics is increasing among the public. In order to confer 
their beneficial effect, probiotic bacteria needs to interact with the host cells. 
This so-called probiotic-host cross-talk is complex and knowledge about the 
details is limited. The overall aim of this thesis work was to provide new 
information on probiotics-host interactions and, in particular, mechanisms of L. 
reuteri probiosis in the GI tract. 
As a part of this research, L. reuteri strains were equipped with reporter genes 
and genes encoding putative probiosis factors were inactivated. These new 
variants of L. reuteri were used to investigate the transit, location and 
interactions with the host GI tract. Furthermore, the effects of L. reuteri strains
on complex junction proteins and immune mediators, and the importance of 
these interactions on mucosal permeability, were investigated. Specific 
objectives of the studies described in Papers I, II, III and the Preliminary study 
were to:
¾ Develop new genetic tools through e.g. generation of genetically modified L. 
reuteri, including strains expressing luminescence and fluorescence and 
strains in which genes of putative importance for probiosis were inactivated
(Paper I and Paper III).
¾ Investigate these labelled L. reuteri strains by: 
a) In vivo and ex vivo imaging, to study the real-time transit and location 
of L. reuteri along the GI tract (Paper I).
b) In vitro flow cytometry, to study plasmid persistence and fluorescence 
microscopy in order to evaluate adherence of the bacteria to epithelial 
cells (Paper I).
¾ Investigate the effect of L. reuteri strains on the mucosal barrier, apical 
junctions and immune mediators using an infection model (Paper II).
¾ Investigate the importance of specific genes, putatively involved in L. reuteri
probiosis, for a protective effect on mucosal integrity and acute colitis (Paper 
III). 
¾ Investigate the effect of L. reuteri strains on activation and degranulation of 
mast cells in vitro (Preliminary study).
2 Aims 
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In this chapter, the materials and methods used to conduct the work described 
this thesis, including in the preliminary study investigating the interactions 
between L. reuteri and mast cells, are reviewed. The methods are described in 
detail in Papers I, II and III.  
3.1 Bacterial growth conditions (Papers I and II, 
Preliminary study) 
All Escherichia coli strains were cultured on Luria-Bertani agar or in broth with 
shaking at 37 °C. All L. reuteri strains and mutants were cultured at 37 °C in de 
Man Rogosa Sharpe (MRS) broth or under anaerobic conditions on MRS agar. 
Strains harbouring plasmids were grown in the presence of erythromycin (400
ȝJP/-1 for E. coli DQGȝJP/-1 for L. reuteri).
3.2 Genetic engineering of L. reuteri
3.2.1 Construction of plasmids and generation of L. reuteri fluorescent 
and luminescent strains 
A CBRluc::mCherry cassette was synthesised and cloned into the inducible 
vector pSIP411. The construct was first electroporated into two intermediate 
cloning hosts: E. coli PK401 and Lactococcus lactis MG1363. After creating 
also constructs with separated CBRluc and mCherry markers, all three variants 
were then electroporated into the L. reuteri strains R2LC and ATCC PTA 6475.
The recombinant strains were named 6475-CBRluc-mCherry, 6475-
mCherry, R2LC-mCherry and R2LC-CBRluc. The sequences of the constructs 
were verified by PCR and sequencing. 
3 Outline of materials and methods
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3.2.2 Generation of mutant (Paper III)
Generation of targeted point mutations in the chromosome, without the need for 
selection, can be achieved by oligonucleotide-mediated recombineering (ssDNA 
recombineering) technology (van Pijkeren and Britton, 2012). The technique has 
been utilised for inactivation of a number of L. reuteri 6475 genes, e.g. in other 
studies cell- and mucus-binding protein A (cmbA; hmpref0563_10633), LPxTG-
anchored amidase (hmpref0536_10802), propanediol dehydratase, large subunit 
(pduC) (involved in production of reuterin) and sortase (srtA); and in this study 
chaperon DnaK (dnaK). 
3.3 Bacteria preparations for IPEC-J2, mast cell and 
murine models  
The strains of L. reuteri were grown in 10 mL MRS broth, the optical density 
(OD) was measured and the bacterial cells were washed once with PBS. Prior to 
the experiment, the IPEC-J2 monolayer (Papers I-III) and mast cells 
(Preliminary study) were washed and cultured with antibiotic-free medium 
overnight.  
The mast cells were pre-treated with L. reuteri ATCC PTA 6475, DSM 
17938, 1563F and R2LC for 6 hours at a multiplicity of infection (MOI) of 50 
(Preliminary study) and the epithelial cells were pre-treated with L. reuteri
strains ATCC PTA 6475, DSM 17938 and 1563F (Paper II), and the 6475 
mutants (6475 dnaK࣓, 6475 pduC࣓, 6475 amidase௅, 6475 cmbA௅and 6475 srtA௅)
(Paper III) with 100 MOI.  
For Paper II and Paper III, an infection model was established by infecting 
the IPEC-J2 cells with ETEC 853/67, a clinical isolate (Handl et al., 1988), at 
MOI 10 for 4 or 6 hours.  
In Paper II, in order to measure the expression of tight junction (TJ) proteins 
and inflammatory cytokines, IPEC-J2 cells were pre-treated with L. reuteri
strains for 6 hours at 100 MOI. Cells were thereafter washed twice with 
antibiotic-free medium and challenged with ETEC (10 MOI) for 4 hours. 
In Paper III, the L. reuteri strains were cultured in 400 mL MRS broth 
overnight at 37 °C. The bacteria were then washed with PBS and suspended in 
4 mL freezing buffer with glycerol and stored frozen (-70 °C) until use.  
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3.4 Animal experiments (Papers I and III, Preliminary 
study) 
3.4.1 Animals
C57BL/6 female mice weighing between 25 and 35 g (Preliminary study), 
BALB/c male mice weighing between 18 and 35 g (Paper I) and 60 C57BL/6 
male mice aged 6 to 8 weeks (Paper III) were used. The animals were maintained 
under standardised conditions at 21-22 °C with daily illumination of 12 h 
darkness/12 h light. The animal experiments were performed with the 
permission of the Swedish Laboratory Animal Ethics Committee in Uppsala and 
according to the guidelines of the Swedish National Board for Laboratory 
Animals. 
3.4.2 In vivo and ex vivo imaging of L. reuteri strains in mice (Paper I) 
The 6475-CBRluc-mCherry and R2LC-mCherry strains were diluted in PBS and 
the induction peptide and D-Luciferin were added to 1 mL of bacterial 
suspension. Different doses of recombinant L. reuteri (1×105-1×1010 CFU) were 
used. The bacterial mixtures were gavaged orally following anaesthesia of the 
mice with 2% isoflurane. In order to study the transit of the recombinant bacteria 
in the GI tract, in vivo images were taken 0, 60, 120 and 180 minutes post-gavage 
by a Spectrum pre-clinical in vivo imaging system (IVIS). For ex vivo imaging, 
the GI tract was removed at different time points (0, 60, 120 and 180 min post-
gavage) and images were taken using an IVIS camera, with air injection or not, 
as described in earlier studies (Foucault et al., 2010, Rhee et al., 2011). The in 
vivo fluorescence and luminescence were expressed as average radiance 
(p/sec/cm2/sr). 
3.4.3 DSS-induced colitis and evaluation of the disease activity index 
(DAI) (Paper III)
Three independent experiments were performed using in total 60 mice randomly 
distributed into different treatment groups. The experimental time line is 
described in Figure 4. In brief, three days prior to induction of colitis the mice 
were gavaged with PBS (control group), L. reuteri 6475 wild type and the three 
mutants 6475 cmbA௅, 6475 dnaK௅ and 6475 pduC௅, all with a dose of 1×108 CFU. 
The acute colitis was induced by adding 2.5-3% (w/v) DSS to the drinking water 
for 7 days.  
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Figure 4. Time plan of the colitis experiment. Colitis in mice was induced by dextran sulphate 
sodium (DSS) after pre-treatment with Lactobacillus reuteri. 
The severity of the colitis was examined by evaluating the disease activity 
index (DAI) each day during a period of 8 days with a scale (0-4) described 
previously by Cooper and co-workers (Cooper et al., 1993, Cooper et al., 2000).
3.5 Mammalian cell culture 
3.5.1 Epithelial cell culture (Papers I- III) 
The IPEC-J2 cell line was employed for evaluation of the interaction with 
epithelial cells. This is a nontransformed epithelial cell line that has been derived 
from the small intestine of a unsuckled piglet (Berschneider, 1989). IPEC-J2 
cells are analogous to the human gut physiology (Zakrzewski et al., 2013). The 
cells were cultured and maintained in complete Dulbecco’s modified Eagle’s 
medium (DMEM)/F-12 Ham at 37 °C in an atmosphere of 5% CO2.  
5×105 cells were seeded per transwell filter and thereafter allowed to polarise 
(Papers II and III). A high seeding density is required to prevent cell proliferation 
(Cereijido et al., 1978). It has been shown that IPEC-J2 cells grown on transwell 
filters can differentiate to enterocytes that exhibit enterocyte characteristic such 
as microvilli, TJ and production of cytokines (Roselli et al., 2007, Brosnahan 
and Brown, 2012).  
3.5.2 Isolation and generation of murine peritoneum-derived mast cells 
(PCMCs) (Preliminary study)  
In the Preliminary study, a primary murine mast cell model (peritoneal cell-
derived mast cells) (PCMCs) was employed to study the effect of L. reuteri on 
mast cell activation and degranulation. Resident peritoneal mast cells are mature 
serosal-type and differentiated mast cells that can be expanded in culture to 
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generate homologous cells and the characteristics of peritoneal mast cells is 
almost retained (Malbec et al., 2007). Peritoneal cells were collected from wild-
type C57BL/6 mice and PCMCs were isolated and established according to a 
protocol described elsewhere (Malbec et al., 2007). In brief, PCMCs were 
established by culture of peritoneal cells in DMEM plus GlutaMAX (Gibco, 
Invitrogen) supplemented with 10% supernatant of transfected Chinese hamster 
ovary cells (CHO cells) with an expression vector constitutively expressing 
murine stem cell factor (SCF) (kindly provided by Dr. M. Daeron, Pasteur 
Institute, France), 60 ȝg/mL streptomycin, 50 ȝg/mL penicillin, 10% FBS, 100 
ȝM MEM non-essential amino acids and 50 ȝM 2-mercaptoethanol. A culture 
time of 4-5 weeks was used for the experiment and the medium was changed 
every 4-5 days. 
3.6 In vitro exposure of PCMCs to Lactobacillus reuteri
and measuring of activation and degranulation 
3.6.1 Activation of mast cells (preliminary study)
For the Preliminary study, PCMCs were washed three times in PBS and 
centrifuged for 8 min at 0.4 rcf. Mast cells were re-suspended in antibiotic-free 
medium at a density of 1.5×106 cells/mL and sensitised with IgE anti-DNP (BD 
Biosciences, Pharmingen) at a concentration of 1 g/mL overnight at 37 °C. 
Next day, 0.75×105 CFU/mL of L. reuteri strains (ATCC PTA 6475, DSM 
17938, R2LC and 1563F) corresponding to 50 MOI were added to the mast cells 
for 6 hours (based on our primary results). After 6 hours of incubation, samples 
were collected for the viability test on mast cells using trypan blue staining. The 
excess of IgE, anti-DNP and bacteria was washed away using Tyrode’s buffer 
three times. The mast cells were re-suspended in Tyrode’s buffer and plated at a 
density of 2x106 cells/mL into 24-well tissue plates in triplicate for each 
treatment. To stimulate the mast cells, 0.5 g/mL DNP-HAS was added to the 
cells, followed by a 30 min incubation at 37 °C. For calcium ionophore-mediated 
degranulation, Ca- LRQRSKRUH$6LJPD$OGULFKZDVDGGHGȝ0ILQDO
concentration) to the cells. After stimulation, cells collected by centrifugation 
and both supernatant and cell pellets were saved at -20 °C until analysed.  
For the qPCR experiments, mast cells were stimulated or not stimulated as 
described above, followed by 2 hours of incubation. Cells were collected by 
centrifugation, frozen and stored at -70 ºC. 
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3.6.2  ȕ-hexosaminidase assay (Preliminary study)
,Q WKH 3UHOLPLQDU\ VWXG\ D ȕ-hexosaminidase assay was performed. The 
PCMC pellets were lysed in 250 L of 1% Triton X-100 in Tyrode’s buffer. 
Then 20 L samples of cell lysate (four-fold dilutions) or supernatant were 
loaded in duplicate into a 96-well plate (flat bottom, Nunc), followed by 80 L 
of the substrate 1 mM p-nitrophenyl N-acetyl-ȕ-D-glucosamine (Sigma Aldrich) 
diluted in 0.05 M citrate buffer (pH 4.5), and the plate was incubated at 37 °C 
for 1 hour. The reactions were stopped and quenched with 200 L of 0.05 M 
NaCO3 buffer (pH 10) and the plate was read at 405 nm. Results are shown as 
WKHSHUFHQWDJHRIȕ-hexosaminidase released from the cells.
3.7 Expression of complex junction proteins and pro-
inflammatory cytokines  
3.7.1 Extraction of protein and immunoblotting
In Paper II, total protein in IPEC-J2 cells was extracted using lysis buffer from 
the mirVana PARIS Kit. The cell lysate was centrifuged and the supernatant 
collected. The protein concentration was measured with a protein assay kit using 
a Qubit 3.0 Fluorometer. The proteins were separated by electrophoresis and 
transferred to PVDF membranes. 
After blocking, the membranes were incubated with the desired antibodies. 
The primary antibodies used in Paper II were as follows: rabbit polyclonal anti-
ZO-1, anti-cadherin-1 and anti-ȕ-DFWLQ 7KH ORDGLQJ FRQWURO ZDV ȕ-actin.
Thereafter, the membranes were washed and incubated with HRP-conjugated 
goat anti-rabbit sera and washed. A chemiluminescence detection reagent (ECL) 
was used to visualise protein bands. Densitometry was carried out to quantify 
the bands. 
3.7.2 RNA isolation and expression analysis by real-time PCR
The total RNA from the IPEC-J2 (Paper II) and mast cells (Preliminary study) 
was isolated using a NucleoSpin RNA II Kit according to the manufacturer’s 
LQVWUXFWLRQV$SSUR[LPDWHO\ȝJ51$ZDVUHYHUVH-transcribed to cDNA. In the 
Preliminary study, the following PCR protocol was used: 95°C, 10 min; 40 times 
(95°C, 30 s; 57°C, 20 s; 72°C, 20 s). For both studies, a melting curve 
programme (60-95°C with a heating degree of 0.1°C/s and continuous 
fluorescence measurement) was used. Relative gene expression was quantified 
using three technical replicates for each sample. The relative expression ratio of 
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IL-6 and TN)Į 3DSHU ,, ,O-6 and IL-13 (Preliminary study) was calculated 
based on the Ct deviation of treated samples compared with untreated and real-
time PCR efficiencies and normalised against the expression levels of the 
UHIHUHQFH JHQHV ȕ-actin (Paper II) and GAPDH (Preliminary study) using 
methods 2-¨¨F7 (Preliminary study) and Pfaffl (Paper II).
Table 1. List of primers used in the Preliminary study on mast cell-Lactobacillus reuteri 
interactions
Gene name       Source    Primer sequence   3URGXFWVL]HES70ᄶ&
IL-6 Mouse )ƍ$*$&$$$*&&$*$*7&&77&$*$*$-3 148       71
5ƍ7$*&&$&7&&77&7*7*$&7&&$*&-ƍ
1L-13 Mouse )ƍ&$*&$7**7$7**$*7*7**-ƍ 117       67
5ƍ$**&&$7*&$$7$7&&7&7*-ƍ
GAPDH Mouse )ƍ&$&7*$*&$7&7&&&7&$&$-3          111    68  
5ƍ*7***7*&$*&*$$&777$7-ƍ
3.8 Statistical analyses 
All experiments in Paper II were performed with triplicate or quadruple 
independent seedings with three technical replicates. In Paper III, the 
comparison of 6475 wild types and the mutants was performed with three 
technical replicates. Statistical differences in transepithelial electrical resistance 
(TEER) and FITC-dextran between all treatments were assessed using one-way 
ANOVA followed by a Student’s t-test (Papers II and III). Statistical analyses 
of the real-time qPCR (Paper II and Preliminary study) and immunoblotting 
experiments (Paper II) were conducted with one-way ANOVA analysis followed 
by Tukey’s multiple comparisons post-test and a Student’s t-test, respectively. 
Significant differences between groups analysed for effects on DAI (Paper III) 
and mast cell degranulation (Preliminary study) were evaluated using two-way 
ANOVA and one-way ANOVA, followed by Tukey’s multiple comparisons 
post-hoc test respectively. In all experiments, differences were considered 
significant at pDQGGDWDZHUHSUHVHnted as mean ± standard error of the 
mean (SEM). All statistical analyses were carried out with the JMP statistical 
software Pro 11.

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This chapter provides an overview of the main results of Papers I-III and the 
Preliminary study.
4.1 In vitro and in vivo application of fluorescent and 
luminescent variants (Paper I) 
4.1.1 In vitro applications of fluorescence- and luminescence-labelled L. 
reuteri and assessment of plasmid persistence
The signal intensity of the recombinant luminescent and fluorescent L. reuteri
generated and the persistence of the pSIP-CBRluc-mCherry, pSIP-CBRluc and 
pSIP-mCherry plasmids were evaluated in the absence of selection pressure. The 
6475-CBRluc-mCherry, 6475-CBRluc and R2LC-mCherry strains were 
cultivated for 10 days in the absence of antibiotics, which caused loss of the 
plasmids in a time-dependent manner, as shown by flow cytometry (FCM), plate 
counts (PC) and a luciferase assay. Data from the luciferase assay showed that 
the smaller plasmid, pSIP-CBRluc, was more stable in R2LC-CBRluc than the 
larger plasmid, pSIP-CBRluc-mCherry, in 6475-CBRluc-mCherry after 
bacterial serial subculture (77% compared with 12% at day 1, 7% compared with 
0% at day 10).  
The two methods PC and FCM were compared in experiments evaluating 
plasmid persistence in fluorescence-producing bacteria. The persistence of pSIP-
mCherry in R2LC-mCherry and 6475-mCherry was detected to be ~20 and ~ 35 
%, respectively, when using PC and 60 and 95 %, respectively, when using 
FCM, after 4 days of bacterial subculture. For 6475-CBRluc-mCherry, the 
plasmid could not be detected at day 4 of serial subculture, as shown by both PC 
and FCM assays. In contrast, over a period of 10 days of daily subculture of the 
bacteria in the presence of antibiotics, signal intensity was stable for all 
4 Main Results
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fluorescent recombinants and 6475-CBRluc-mCherry exhibited the lowest 
(1.8×103 p/s) and R2LC-mCherry the highest (2.9 ×104 p/s) signal intensity 
(p<0.001) shown by FCM. The signal stability for the fluorescent bacteria was 
evaluated by fluorescence microscopy (FLM) and signal heterogeneity was 
observed among plasmid-bearing cells.  
Furthermore, the mCherry signal was affected by both pH and duration of 
induction time. An improvement in signals was observed at neutral pH compared 
with pH 4.6 when using FLM. In addition, the signal intensity improved 
significantly (p<0.001) with a long induction period (~20 hours) compared with 
a short induction period (~4 hours) for the mCherry-producing strain (6475-
mCherry).
4.1.2 In vivo applications of recombinant L. reuteri
In vivo and ex vivo transit and location of luminescence-producing strains of L. 
reuteri were assessed and visualised after intragastric administration of different 
doses of the bacteria (from 1×105 to 1×1010 CFU/mouse) using an in vivo
imaging system (IVIS). Using whole body imaging, the highest luminescence 
signal from 6475-CBRluc-mCherry and R2LC-CBRluc (3.8×108 and 7.6×106
p/sec/cm2/sr, respectively) and the fluorescence signal from 6475-CBRluc-
mCherry (2.6×108 p/sec/cm2/sr) were detected in the high dose treatment (1×1010
CFU/mouse). Interestingly, the luminescence signal of the lowest dose of 6475-
CBRluc-mCherry (1×105 CFU/mouse) could also be detected. 
Observations of the transit and location of the two recombinant strains 6475-
CBRluc-mCherry and R2LC-CBRluc varied and indicated a faster transit time 
for 6475-CBRluc-mCherry compared with R2LC-CBRluc at 60 min post-
gavage. Moreover, at 3 h post-gavage, the bioluminescence signals of mice 
given the high dose could still be visualised ex vivo and large numbers of bacteria 
were retained in the stomach.
The fluorescence signal from 6475-CBRluc-mCherry was not detectable 
after 60 min. 
4.2 Lactobacillus reuteri and intestinal permeability 
4.2.1 Protective effect of L. reuteri on epithelial permeability
An infection model of polarised IPEC-J2 monolayers using the ETEC strain 
853/67, a porcine clinical isolate capable of producing different types of 
enterotoxins (Handl et al., 1988), was used. Two different doses (100:1 and 
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1000:1 MOI) of the L. reuteri strains ATCC PTA 6475, DSM 17938, R2LC and 
1563F were employed for pre-treatment of the cells. 
The results indicated that two hours post ETEC-challenge, TEER was 
reduced by 5% for the L. reuteri groups and by 24% in the ETEC-group. After 
4 hours, TEER declined further and reached 96% in the ETEC-group and the 
pre-treatment with all L. reuteri strains could only partly protect the epithelial 
monolayer. A high dose of bacteria preserved higher TEER values compared 
with lower dose significantly (p<0.05).  
The protective effect of the L. reuteri strains against the deleterious effect of 
ETEC on monolayer integrity was more pronounced when measuring the tracer 
FITC-dextran. After 6 hours post-infection, the FITC-dextran permeability was 
decreased by 60-85% for the high dose and 50-70% for the low dose compared 
with the ETEC group. Among the L. reuteri strains tested, ATCC PTA 6475 and 
DSM 17938 showed the highest protective efficacy (Paper II). 
In Paper III, a preliminary experiment was carried out to compare the 
protective effect of L. reuteri 6475 wild type with its derivative mutants on the 
detrimental effect of ETEC on mucosal integrity. In the five mutants evaluated, 
the genes encoding the following proteins had been inactivated: chaperone 
DnaK (dnaK–), propanediol dehydratase, large subunit (pduC–; involved in 
production of reuterin) cell- and mucus-binding protein A (cmbA–), LPxTG-
anchored amidase (hmpref0536_10802௅) and sortase (srtA௅).
Two and four hours post-ETEC challenge of monolayers, there was a 
decrease in TEER of ~60% and ~96 %, respectively, whereas pre-treatment of 
the monolayers with L. reuteri wild type and mutants followed by ETEC 
challenge resulted in a decrease of 10-28% and ~94%, respectively. However, 
there were no significant differences between the mutants and the wild type. In 
addition, FITC-dextran permeability was significantly higher for the ETEC 
control group (100%) compared with the L. reuteri group (14-26%; p<0.05). No 
significant difference was found between treatments with wild type and the 
mutants (Paper III).
4.2.2 Lactobacillus reuteri reverses the deleterious effect of ETEC on 
expression of apical junction proteins  
Expression of E-cadherin and zonula occludens (ZO-1) was quantified by 
Western blot tests (Paper II). Densitometry analysis of the immunoblots revealed 
two bands of size 195 and 187 kDa, corresponding to two different isoforms of 
ZO-1. First, destruction of monolayer integrity was confirmed by evaluating the 
expression of E-cadherin and ZO-1 following ETEC infection. Overall, the 
expression of both E-cadherin and ZO1-187 declined by more than 60%. This 
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effect was reversed by pre-treatment of the monolayers with L. reuteri strains 
DSM 17938 and 1563F, giving two- and three-fold higher expression of E-
cadherin and ZO1-195, respectively (p<0.05).  
In addition, cells pre-treated with strain 1563F exhibited a three-fold increase 
in expression of ZO1-187 compared with the ETEC control group (p<0.05).  
In Paper II, in order to investigate whether L. reuteri could prevent an 
inflammatory response in the epithelial monolayer, IPEC-J2 cells were pre-
treated with L. reuteri for 6 h, followed by infection with ETEC for 4 h, after 
which the mRNA expression of the pro-LQIODPPDWRU\F\WRNLQHV71)ĮDQG,/-6
was evaluated by real-time PCR. Infection of the cells with ETEC increased 
71)Įand IL-6 expression 21-fold and ~six-fold, respectively, compared with 
the control (p<0.05).  
Pre-treatment of the cells with strain DSM 17938 followed by ETEC 
challenge gave a two-fold reduction in IL-6 gene expression (p<0.05). In 
addition, pre-treatment with all three L. reuteri strains decreased mRNA 
H[SUHVVLRQRI71)ĮWZR- to three-fold compared with the ETEC group (p<0.05).
Lactobacillus reuteri downregulates elevated expression of pro-inflammatory 
cytokines induced by ETEC. 
4.2.3 Mode of action of L. reuteri in a DSS-induced acute colitis murine 
model (Paper III)
A ssDNA recombineering technique was used to introduce a site-directed
mutation in the dnaK gene encoding the heat shock protein DnaK. Lactobacillus 
reuteri 6475 wild type and its derivative mutants of chaperon DnaK (dnaK–); 
propanediol dehydratase, large subunit (pduC–); and cell- and mucus-binding 
protein A (cmbA–) were selected for in vivo studies of the probiosis mechanism 
involved in amelioration of inflammation and tissue damage in colitis (Paper 
III). A model of acute colitis was established in mice by administration of 2.5-
3% DSS in drinking water for 8 days. The disease activity index (DAI) was 
calculated by scoring changes in weight loss, stool consistency and blood 
content, as described elsewhere (Cooper et al., 1993, Cooper et al., 2000).  
Three days of pre-treatment of the animals with L. reuteri 6475 (prior to 
induction of acute colitis by DSS) significantly lowered DAI score at day 8 
compared with DSS group. In addition, no significant differences between wild 
type 6475 and the three mutants were observed. However, two of the mutants, 
6475 cmbA- and 6475 dnaK-, had a tendency to decrease their protective effects 
and increase the DAI scores.
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4.3 Lactobacillus reuteri and mast cell activation and 
degranulation 
The aim of the Preliminary study was to determine whether L. reuteri inhibits 
mast cell degranulation as well as pro-inflammatory cytokine synthesis and 
release.
The majority of mast cells are present in mucosal layers, where the body 
encounters the outside environment. Mast cells are a granulated cell type of the 
immune system that can release a variety of pre-made and de novo synthesised 
PHGLDWRUV VXFK DV KLVWDPLQH ȕ-hexosaminidase, proteases, cytokines and 
chemokines upon activation based on the type of stimuli (e.g. IgE-mediated or 
Toll-like receptor-mediated) (Wernersson and Pejler, 2014).  
A pilot study was performed on murine peritoneal cell-derived mast cells 
(PCMC) with three technical replicates. The interaction between PCMCs and L. 
reuteri was assessed and production of some of the mast cell mediators including 
ȕ-hexosaminidase and pro-inflammatory cytokines IL-6 and IL-13 was studied. 
To examine the effect of L. reuteri on mast cell degranulation, cells were pre-
treated with L. reuteri prior to the IgE-PHGLDWHG VWLPXODWLRQ DQG ȕ-
hexosaminidase release from the cells was measured. As a positive control, Ca-
ionophore was used, which caused strong degranulation.  
Six hours of pre-treatment of the mast cells with four strains of L. reuteri
(ATCC-PTA 6475, DSM17938, R2LC and 1563F) did not affect the viability of 
mast cells (Figure 5A). Lactobacillus reuteri strains did not degranulate the mast 
FHOOVSULRUWRVWLPXODWLRQH[FHSWIRUZKLFKFDXVHGȕ-hexosaminidase 
release. Moreover, L. reuteri strains did not prevent the degranulation of PCMCs 
after mast cells had been stimulated (Figure 5B). 
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Figure 5. Effect of Lactobacillus reuteri on mast cell viability and degranulation. The peritoneal 
cell-derived mast cell (PCMCs) were pre-treated with four different strains of L. reuteri and then 
stimulated using IgE anti-DNP followed by DNP-HAS (IgE/Ag). Prior to stimulation, the viability 
RIPDVWFHOOZDVHYDOXDWHG$7KHȕ-hexosaminidase activity of the PCMCs was assessed before 
and after stimulation (B). Data are represented as relative activity in supernatant/total activity and 
represented as the mean (±SEM) of three technical replicates. Columns that do not share similar 
letters are significantly different (pDVGHWHUPLQHGE\RQH-way ANOVA followed by Tukey's 
post-hoc test.
Pre-treatment of mast cells with Lactobacillus reuteri downregulated the 
levels of both IL-6 and IL-13. More specifically, a trend of lower expression 
levels of both IL-6 and IL-13 was seen for cells treated with all of the L. reuteri
strains compared with the untreated cells. However, although the pre-treatment 
lowered the amount of target RNA compared with the untreated cells, no 
significant differences were found between untreated cells and cells pre-treated 
with L. reuteri except for expression of IL-6 from cells pre-treated with R2LC 
(p<0.05) (Figure 6A and 6B).  
Comparing the stimulated cells (both pre-treated and untreated) to the control 
revealed upregulation of IL-6 and IL-13 by approximately 10-fold in IgE/Ag-
control compared with the control. Interestingly, two of the L. reuteri strains 
were able to reduce this prominent increase in both cytokines after stimulation 
compared with the IgE/Ag-control. Lactobacillus reuteri 6475 counteracted the 
upregulation of IL-13 and IL-6 caused by stimulation, to levels lower than that 
of the control (17-fold and 20-fold, respectively) (Figure 6A and 6B). The 1563F 
strain also downregulated expression of IL-13 and IL-6 by ~ three-folds. In 
addition, a trend for decreased expression was observed for DSM17938 and 
R2LC (Figure 6A and 6B).  
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Figure 6. Effect of Lactobacillus reuteri on gene expression of peritoneal cell-derived mast cell 
(PCMC) pro-inflammatory cytokines. The PCMC treated or not with L. reuteri strains for 6 h. The 
expression of IL-13 (A) and IL-6 (B) in response to IgE anti-DNP and DNP-HAS (IgE/Ag) 
stimulation or in the absence of stimuli was evaluated against an IgE/Ag control. The results were 
considered significant at p<0.05 by one-way ANOVA with Tukey’s post-hoc test and columns 
labelled with different letters are significantly different. The data represent the mean (±SEM) of 
three technical replicates.   
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 Genetic engineering of L. reuteri and in vivo and in
vitro applications of recombinant L. reuteri (Paper I)
In Paper I, in vivo and in vitro applications of recombinant fluorescent and 
luminescent L. reuteri were employed and the recombinant bacteria were used 
to study plasmid persistence and transit and location of L. reuteri in the GI tract 
of mice.
The work in Paper I started with genetic engineering of L. reuteri and 
labelling of L. reuteri with reporter genes, namely the bioluminescence reporter 
click beetle luciferase (CBRed) and red fluorescent mCherry, which have 
recently been used for experimental bioluminescent and fluorescent imaging in 
the probiotics field.  
A large number of reporter proteins (e.g. luminescence and fluorescence 
proteins) are available as markers that allow easy detection of labelled cells in 
complex microbial ecosystems. From the first discovery of green fluorescent 
protein (GFP) (Shimomura et al., 1962), a range of fluorescent proteins have 
been discovered and developed and have been expressed in prokaryotic and 
eukaryotic organisms (Chalfie, 1994). However, most research on fluorescence 
reporter genes has been directed toward optimisation of fluorescence, 
improvement of photo-stability, decreasing the maturation time and increasing 
the brightness (Shaner et al., 2005). mCherry was chosen in this thesis for 
numerous reasons. It has a monomeric structure that make it an ideal choice for 
protein fusions, it is non-toxic to its host even in high amounts, it is resistant to 
photo bleaching, it has high stability and it is easy to detect under diverse in vivo
and in vitro conditions (Shaner et al., 2005).  
Besides mCherry, the CBRed from Pyrophorus plagiophthalamus was 
chosen. The reason for the choice was the versatile use of this protein in gene 
expression studies and for bioluminescence imaging (BLI), despite the 
5 Main Discussion
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inevitable need for oxygen for the reaction between the luciferase enzyme and 
its substrate to generate visible light (Gheysens and Mottaghy, 2009). 
In Paper I, the mCherry and CBRluc genes were codon-optimised for 
Lactobacillus reuteri and successfully expressed in the R2LC and 6475 strains. 
The importance of codon optimisation has been shown previously and 
fluorescence and luminescence genes have been codon-optimised for a number 
of bacteria, including lactobacilli, in order to maximise expression of the reporter 
(Landete et al., 2016). A good example is codon optimisation in Mycobacterium 
tuberculosis, which increases expression of a luminescence gene by 30-fold 
(Andreu et al., 2010).  
After generation of the fluorescence-labelled L. reuteri, its possible use in 
evaluation of plasmid persistence was investigated. For this, an alternative 
technique based on flow cytometry (FCM) for assessing plasmid persistence was 
introduced and compared with the classical plate count (PC) method and replica 
plating. The hypothesis tested was that FCM is a good alternative to the PC 
method and that the latter laborious method can be replaced by FCM for large-
scale screenings in some situations. It was found that the plasmid stability 
profiles for all recombinant strains were virtually identical (when evaluated by 
both FCM and PC), showing that the plasmids were gradually lost and that a 
selection force is required for plasmid persistence. When the two methods were 
compared, the only difference found was a higher plasmid loss rate of 6475-
mCherry detected by PC compared with FCM. A previous study also found 
similar plasmid persistence profiles by both PC and FCM (Loftie-Eaton et al., 
2014). 
Plasmid persistence in bacterial populations has previously been studied 
using replica plating (Cooper and Heinemann, 2000, Deane and Rawlings, 
2004). In agreement with previous research, Paper I showed that the 
conventional culture-based methods have several major drawbacks, such as 
being time-consuming, labour-intensive and challenging to use for high-
throughput screening. Furthermore, the PC method usually generates uncertain 
results associated with differences between low-plasmid/free-plasmid and high-
plasmid containing bacterial growth rates, where the latter gradually 
accumulates in the culture (Lau et al., 2013a). Thus, other methods such as FCM, 
culture-based microscopy and real-time quantitative PCR (qPCR) have recently 
been tested and suggested to be possible alternatives for assessing plasmid 
persistence (Bonot and Merlin, 2010, Loftie-Eaton et al., 2014, Bahl et al., 2004, 
Lau et al., 2013b).  
It was concluded in Paper I that FCM is a competitive alternative to plate 
count assays for studies of plasmid persistence. Some of the advantages of using 
FCM in studying recombinant labelled L. reuteri and plasmid persistence are: 

49
the high sensitivity, allowing detection of bacteria with low fluorescence signals 
in complex bacterial populations, allowing large-scale screening, and the 
absence of a need for selectable markers, making it a powerful analytical 
technique for evaluation of plasmid persistence. 
Despite the presence of many reporter proteins, application of 
bioluminescence reporters for Lactobacillus species is essentially undeveloped 
and Paper I describes the only successful luminescence construct for L. reuteri. 
Besides that, there are only a few reports for other Lactobacillus species (Daniel 
et al., 2013, Landete et al., 2015). However, there are more reports of utilising 
different fluorescence-producing bacteria in vivo. Green fluorescent protein has 
been used to detect bacteria in chickens (Yu et al., 2007) and goats (Han et al., 
2015). Plasmids containing mCherry have also been used to study the 
colonisation of L. plantarum in a germ-free zebrafish model (Russo et al., 2015)
and in the GI tract of mice (van Zyl et al., 2015).  
Next, the successfully generated L. reuteri 6475-mCherry, 6475-CBRluc-
mCherry, R2LC mCherry and R2LC-CBRluc were used for in vivo and ex vivo
studies. It was found that expression of the reporter proteins from these 
recombinant strains facilitated tracking of the bacteria in the GI tract. This is an 
important approach to study interactions between probiotic species and the host. 
The Caliper in vivo imaging system (IVIS), which is one of the most widely 
used optical imaging systems, is equipped with a highly sensitive 
thermoelectrically cooled CCD camera (Caliper Life Sciences, Hopkinton, MA, 
USA) (Gheysens and Mottaghy, 2009). The IVIS approach allowed monitoring, 
in real time, of the transit of different doses of both luminescent and fluorescent 
L. reuteri and a dose as low as 105 luminescent bacteria/mouse or a dose of 1010
fluorescent bacteria/mouse could be detected.
5.2 Lactobacillus reuteri counteracts mucosal 
inflammation induced by an enteric pathogen (Paper 
II)
The intestinal barrier consist of several layers and is highly regulated 
(Scaldaferri et al., 2012). It is known that a balance between selective passage 
of immunogens across the mucosal barrier and the resulting immune response is 
necessary for intestinal haemostasis (Menard et al., 2010). A non-selective 
increase in passage of antigens, as well as microbes, causes inflammation and 
further disruption of the mucosa.  
Paper II studied mucosal integrity and function in response to enterotoxigenic 
E. coli (ETEC) and L. reuteri in vitro and investigated whether L. reuteri could 
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ameliorate the detrimental effect of ETEC on the mucosal barrier in the course 
of an in vitro infection. ETEC 853/67 is a toxin-producing isolate (Handl et al., 
1988), which was used in Paper II for establishment of an infection model of 
non-transformant small intestinal cells of pig origin (IPEC-J2) (Geens and 
Niewold, 2010, Brosnahan and Brown, 2012). The model has been used 
previously to study the effects of probiotics on the intestinal barrier (Liu et al., 
2014, Yang et al., 2015b, Zhang et al., 2015). 
Initially, the effect of the pathogen on the mucosal barrier was evaluated and 
it was observed that the destruction of the mucosal barrier by ETEC was linked 
to modulation of the paracellular and transcellular pathways. This was detected 
by a decrease in transcellular electric resistance (TEER) and increase in 
permeability to FITC-dextran (4 kDa), as found in previous studies (Liu et al., 
2015, Yang et al., 2015a).  
The findings in Paper II indicated that the damage to the mucosal barrier by 
ETEC was associated with modulation of apical junction complex proteins, 
which was detected as a strong decrease in E-cadherin and ZO1-187. 
Previous studies have demonstrated that pathogens, including ETEC, can 
alter the intestinal barrier function through different mechanisms, for instance 
either through production of toxins that are able to activate the myosin light 
chain kinase, which leads to weakening of the endothelial cell-cell adhesion and 
barrier function  (Johnson et al., 2010, Philpott et al., 1998, Shen et al., 2010) or 
production of proteases that alter the structure and function of junctional proteins 
and initiate re-organisation of the cytoskeleton (Blum and Schiffrin, 2003, de 
Vrese and Marteau, 2007). Furthermore, downregulation of mucin production, 
lysis of epithelial cells and induction of apoptosis, cell cycle arrest and growth 
inhibition, all of which facilitate invasion of pathogens into the intestinal cell 
layer, have been studied extensively (McGuckin et al., 2011).  
In addition, hijacking of cellular molecules and signalling pathways of the 
host, including upregulation of pro-inflammatory cytokines, is often part of the 
pathogenic process (McGuckin et al., 2011). It was found in Paper II that 
disruption of the mucosal barrier by ETEC was associated with a strong increase 
LQ71)Į DQG ,/-6 expression, and the afore-mentioned modulation of apical 
junction proteins, which is in agreement with previous studies (Shimazu et al., 
2012, Wang et al., 2016).  
How probiotics can communicate with epithelial cells and the mechanism by 
which L. reuteri exerts its probiosis activities on impaired epithelial barrier 
caused by infection were studied. 
Paper II showed that L. reuteri could partly reverse or counteract the 
inflammatory and mucosal damage processes. Attenuation of inflammation of 
intestinal epithelial cells by L. reuteri was found to be through downregulation 
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of expression of TNFĮ DQG ,/-6. Upon downregulation of the elevated 
expression of the pro-inflammatory cytokines by L. reuteri, the expression of 
ZO-1 and E-cadherin was stabilised, and as a result further damage to the 
intestinal barrier was slowed down. The results indicated that there might be a 
OLQN EHWZHHQ WKH LPPXQH PHGLDWRUV 71)Į DQG ,/-6 and the tight junction 
proteins (Paper II), a correlation reported previously in studies conducted in vitro
(Suzuki et al., 2011, Tazuke et al., 2003, Ye and Ma, 2008) and in vivo (Wang 
et al., 2001, Yang et al., 2003). 
 In order to study the importance of the dose, the effects of a low (100 MOI) 
and a high dose (1000 MOI) of L. reuteri were compared. The higher dose 
showed better protection and maintenance of the monolayer in the late phase of 
infection. Of course, a study on cultivated epithelial cells is far from a human 
clinical trial, but investigations of the dose effect in simple models can provide 
valuable information. In fact, studies on human and animals have demonstrated 
that the beneficial effect of probiotics can be dose-dependent (Ouwehand, 2016, 
Fang et al., 2009, Suo et al., 2012). Probiotics for humans have been used at 
doses between 107 and 1011 CFU (Weizman et al., 2005, Gionchetti et al., 2000, 
Ouwehand, 2016).  
As known, probiotics are described as living microorganisms which, when 
administered in adequate amounts, confer health benefits ( Joint FAO/WHO 
Group, 2002). However, there is no description or definition of an ‘adequate 
dose’ for humans. Proper probiotic dosage with concern to safety and 
effectiveness has not been systematically studied in human, due to high 
complexity and the high costs of clinical trials. Apart from general criteria (body 
weight, age and health endpoint) possibly affecting the dose, genetic 
background, microbial community, diet, route of administration and, last but not 
least, the manufacturing process (e.g. fresh or freeze-dried bacteria) make the 
matter even more complex. 
It was concluded in Paper II that L. reuteri exerts protective effect on leaky 
intestinal barrier induced by ETEC through stabilisation of tight junction ZO-1, 
adherens junction E-cadherin and the pro-LQIODPPDWRU\F\WRNLQHV71)ĮDQG,/-
6.
5.3 Effect of L. reuteri wild type and mutants on mucosal 
integrity and inflammation using DSS-induced colitis 
and in vitro infection models (Paper III)  
Paper III attempted to identify genes of L. reuteri 6475 involved in the beneficial 
effects seen on mucosal integrity and inflammation in Paper II and mucosal 
damage in an ulcerative colitis model. Therefore, five mutants in which the genes 
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encoding chaperone DnaK (dnaK–), propanediol dehydratase, large subunit 
(pduC–), cell- and mucus-binding protein (cmbA–), LPxTG-anchored amidase 
(amidase௅), and sortase (srtA–) had been inactivated were evaluated in a mice 
colitis model and an infection model with IPEC-J2 cells.
The study was initiated by generation of mutants using a recombineering 
technology. A comparative pilot study of 6475 wild type and its derivative 
mutants, dnaK–, pduC–, cmbA–, amidase௅ and srtA– was carried out on polarised 
IPEC-J2 monolayers. It showed that pre-treatment of the monolayers with both 
the wild type and the mutants counteracted the inflammation and delayed the 
onset and progression of infection by ETEC.  
In conclusion, no significant differences of FITC-dextran permeability, 
TEER and protection of monolayer integrity were observed between 6475 wild 
type and the mutants. This in vitro study was a pilot and should be repeated to 
confirm the results obtained. 
In addition to the in vitro study, 6475 wild type and three of the mutants, 
dnaK-, pduC– and cmbA–, were evaluated for their protective effect on DSS-
induced acute colitis of mice.
During recent decades, several animal models of IBD have been developed 
and accepted. Chemically induced murine models of IBD are the most 
commonly used. In Paper III, chemically induced colitis was established by 
administration of 2.5-3% DSS, (C6H7Na3O14S3)n in the drinking water for 7 
days. DSS is one of the most commonly used agents for the induction of acute 
and chronic IBD (Barnett and Fraser, 2011). It is believed that DSS acts through 
disruption of the epithelial integrity, and that the model clinically and 
histopathologically resembles ulcerative colitis (Neurath et al., 1995, Alex et al., 
2009) and that the results obtained can be translated into human disease (Melgar 
et al., 2008).  
A protective effect of L. reuteri 6475 wild type on DSS-induced colitis was 
observed in Paper III. However, none of the mutants differed significantly from 
the wild type, although two mutants, 6475 cmbA௅ and 6475 dnaK௅, had a 
tendency to lose their beneficial effect. The data indicated that none of the genes 
plays a major role for the protective effect of 6475 on colitis. The protective 
effect of L. reuteri 6475 on the onset and progression of acute colitis in mice has 
been demonstrated previously (Peña et al., 2004). There are number of studies 
illustrating the importance of a single gene in association with a physiological 
function of L. reuteri, or its beneficial effect on mucosal integrity. Cell- and 
mucus-binding protein A (CmbA) is reported to be important in adherence of 
the bacteria to intestinal epithelial cells and mucus in vitro (Jensen et al., 2014).
It has been demonstrated that inactivation of any one of the three genes, histidine 
decarboxylase pyruvoyl type A (hdcA), hdcB and histidine/histamine antiporter 
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(hdcP), in the histidine decarboxylase gene cluster leads to loss of the TNF-
inhibitory activity of L. reuteri 6475 (Thomas et al., 2012). Those authors 
demonstrated in a later study that dihydrofolate synthase (FolC2) is essential for 
suppression of TNF production by activated human monocytes, and concluded 
that the gene is important for the anti-inflammatory effect of L. reuteri 6475 in 
a TNBS-induced acute colitis model (Thomas et al., 2016).  
However, a recent study showed that inactivation of the LPxTG-anchored 
amidase improved the anti-inflammatory response and lowered IL-8 expression 
(Jensen et al., 2015). 
Due to the complexity of probiotics-host interactions, it is likely that more 
genes that play key roles in L. reuteri probiosis and contribute to the beneficial 
effects of L. reuteri related to human health and intestinal functionality remain 
to be discovered. In addition, the combined effect of several genes are perhaps 
even more likely to have a strong impact on the physiology of the bacteria and 
its health-related beneficial effects.  
5.4 Lactobacillus reuteri and mast cell activation and 
deregulation (Preliminary study)
In the Preliminary study, the effect of L. reuteri strains on IgE/antigen-induced 
degranulation was investigated using murine peritoneal cell-derived mast cells 
(PCMCs). This choice made it possible to investigate whether probiotics exert 
their ameliorating effect on inflammation and mucosal integrity, as observed in 
Papers II and III, by affecting innate immune cells such as mast cells in the 
mucosa. Mast cells are involved in the immune response and are located in 
abundance in the lamina propria of the mucosa and also in the submucosal layer. 
It is known that in intestinal mucosa, mast cells not only respond to antigens, but 
also play important roles in mucosal barrier function and transport properties 
(Yu and Perdue, 2001).  
There are growing indications that mast cells can mediate some of the 
beneficial effect of probiotics. Both in vivo (Kim et al., 2008, Sawada et al.,
2007) and in vitro studies (Kawahara, 2010, Kasakura et al., 2009, Cassard et 
al., 2016) have explored the possible links between probiotic effects and mast 
cells. However, studies on mast cell contribution in probiosis mechanisms are 
largely lacking.
The Preliminary study began by evaluating a proper dose of L. reuteri and
viability of mast cells for the experiment. Based on the evaluation results, 6 
hours pre-treatment with 50 MOI of L. reuteri was used. 
7KH UHOHDVH RIPDVW FHOO PHGLDWRUV LQFOXGLQJ ȕ-hexosaminidase and pro-
inflammatory cytokines, was also examined. To determine mast cell 
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GHJUDQXODWLRQDȕ-hexosaminidase release assay was performed. The activation 
of mast cells by L. reuteri was tested and the results demonstrated that L. reuteri
did not activate the mast cells except for one out of four strains (6475). In that 
case, the degranulation was three-fold lower than the stimulatory effect of 
IgE/antigen in the control. It was speculated that L. reuteri 6475 causes 
exocytosis through lowering the pH of the medium. Several environmental 
stimuli such as pH, osmolality, radiation and temperature affect this exocytosis 
(Moon et al., 2014). 
The IgE/antigen-mediated stimulation was used for activation of mast cells. 
Several external stimuli for triggering mast cell degranulation are available and 
among them, IgE receptor crosslinking has been most notably considered for 
degranulation (Metcalfe et al., 1997). Upon IgE/antigen-dependent stimulation, 
GHJUDQXODWLRQ DQG ȕ-hexosaminidase release were observed to be increased 
approximately 60-fold in untreated cells and L. reuteri strains did not exert any 
inhibitory effect on mast cell degranulation.  
Following 6 hours of exposure of mast cells to L. reuteri, a low expression 
of the pro-inflammatory cytokines IL-13 and IL-6 was observed in the 
unstimulated control. Although mast cells are well known for release of a variety 
of mediators with different biological activities upon stimulation, expression of 
pro-LQIODPPDWRU\F\WRNLQHVVXFKDV71)Į ,/-1, IL-5, IL-8, IL-18 and IL-16 
has also been reported for unstimulated human mast cells (Lorentz et al., 2000). 
Consistent with these findings, the Preliminary study also demonstrated 
expression of IL-13 and IL-6 in unstimulated mast cells (control) and showed 
that L. reuteri treatment did not increase expression of these cytokines. 
In addition to the granule-stored mediators (which are stored as preformed 
granules), mast cells are able to synthesise and release many bioactive 
compounds, including cytokines and chemokines, upon exposure to specific 
stimuli (Moon et al., 2014). 
The IgE/antigen-dependent stimulation of the mast cells upregulated the 
expression of IL-13 and IL-6 in untreated cells and L. reuteri counteracted this 
increase intensely, except that the effects of two strains, DSM17938 and R2LC, 
were not significantly different. Downregulation of mast cell pro-inflammatory 
cytokines and chemokines have been observed for a number of probiotics and 
non-pathogenic commensal bacteria. In a study on mast cell-E. coli K12 
interactions, co-incubation of E. coli ZLWKKXPDQPDVWFHOOVUHGXFHGWKH)Fİ5,-
mediated degranulation and downregulated the expression of CCL-4 and CCL-
3 (Kulka et al., 2006). A later study observed that E. coli DSM 17252 was 
capable of preventing IgE-induced degranulation in murine mast cells (Magerl 
et al., 2008). The counteraction of the IgE/antigen mediated degranulation and 
downregulation of the pro-inflammatory cytokines of murine mast cells such as 
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IL-4, IL-13 and TNF-ĮDVZHOODV&2;-DQG)Fİ5,ĮLQUHVSRQVHWRKHDW-killed 
L. reuteri NBRC 15892, has be reported previously (Kawahara, 2010).  
The Preliminary study revealed a link between activation of mast cells, 
degranulation and cytokine upregulation in untreated mast cells. Interestingly, it 
was found that degranulation of mast cells is not always associated with cytokine 
release, and a strong decrease in cytokine expression as a result of treatment with 
L. reuteri in the presence of elevated degranulation was observed. In contrast, 
previous studies have indicated that the release of cytokines can take place 
without noticeable degranulation, for instance upon exposure to a stimulus such 
as lipopolysaccharide (LPS) (Galli et al., 2005, Supajatura et al., 2001). In fact, 
the precise mechanism behind the discriminatory release of mast cell mediators 
in response to stimuli is not well understood. In particular, the sorting 
mechanism of cytokines is unknown and little is known about cytokine storage 
in granules and the pathways involved in initiation of their secretion (Moon et 
al., 2014). The results of the Preliminary study may suggest that IL-6 and IL-13 
are not stored in premade granules like many reported cytokines and chemokines 
(Okayama et al., 1998) and that release is independent of the classical 
GHJUDQXODWLRQSDWKZD\DVKDVEHHQUHSRUWHGIRU71)Į(Olszewski et al., 2007)
and IL-4 (Wilson et al., 2000) (or perhaps similar secretion pathways or 
exocytosis are not applied for these two cytokines). The mechanisms underlying 
this complex occurrence and L. reuteri cannot be explained easily and need 
further investigation. However, it can be postulated that 6 hours of exposure is 
enough time for L. reuteri to downregulate new expression of cytokines in 
response to stimuli, although it failed to inhibit degranulation.  
This preliminary investigation should be repeated with additional 
experiments to confirm the results obtained. These demonstrated that L. reuteri
can ameliorate the cytokine expression caused by mast cell degranulation in 
culture environments. The contribution of mast cells to probiosis mechanisms is 
not known and should be elucidated in future studies. It is possible that L. reuteri
can ameliorate/dampen inflammation caused by mast cell degranulation in 
culture environments.  
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The overall aim of this thesis was to investigate probiotics-host interactions and, 
in particular, to study probiosis mechanisms of L. reuteri in the context of 
intestinal permeability and immune modulation in different models. The main 
findings of this thesis can be summarised as follows: 
¾ The genetic engineering of L. reuteri resulted in generation of a mutant, 6475 
dnaK࣓, and different recombinant stains, including R2LC-CBRluc, 6475-
CBRluc-mCherry and R2LC-mCherry. It was demonstrated that the two 
luminescence and fluorescence reporter genes are suitable markers for 
studying L. reuteri in the complex environment of the GI tract and the data 
indicated high potential of fluorescence producing bacteria for high-
throughput screening of plasmid persistence using flow cytometry. The 
mCherry- and CBRluc-labelled lactobacilli provide the possibility to study 
bacterial transit, location and persistence, but they also have significant 
potential in other in vivo and in vitro studies. For example, they can be used 
to discover the fate of bacterial cells during disease conditions when bacterial 
translocation takes place to the lower layer of the mucosal barrier and to track 
the bacteria in Peyer’s patches, mesenteric lymph nodes and the lymph and 
blood circulation. 
¾ The effects of four wild type strains of L. reuteri (ATCC PTA 6475, R2LC, 
DSM 17938 and 1563F) were studied in an intestinal infection model. It was 
demonstrated that L. reuteri could dampen the inflammation and counteract 
the relaxed cell junction permeability. Lactobacillus reuteri possibly protects 
the tight junction region and confers its beneficial effects on permeability 
through downregulating pro-inflammatory cytokines such as IL-DQG71)Į
and subsequently maintaining and improving expression of the apical 
junction proteins ZO-1 and E-cadherin. Complementary to the evaluated 
6 Concluding remarks and future 
perspectives 
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targeted molecules, the anti-inflammatory effect of L. reuteri should be 
examined by also evaluating the expression of anti-inflammatory cytokines.
¾ The tentative roles of five genes in the probiosis mechanism of L. reuteri was 
examined. In in vitro and in vivo comparative studies, it was demonstrated 
that the chaperon DnaK, propanediol dehydratase large subunit (PduC), cell- 
and mucus-binding protein CmbA, sortase and LPxTG anchored amidase 
may not play major roles in the 6475 probiosis mechanism for attenuating 
intestinal damage and inflammation.  
There is a limited knowledge about genes and factors from L. reuteri strains 
that are directly linked to their beneficial effects and there are relatively few 
reports on L. reuteri mutants that link specific genes to probiosis 
mechanisms. Investigation of more mutants may help to identify genes 
involved in L. reuteri’s mode of action and, since probiotics-host interactions 
may be very complex, inactivation of multiple genes could increase the 
chance to reveal key mechanisms. On the other hand, the results of the in 
vitro study reported here are still preliminary, and there is a need for 
additional experiments to confirm the findings. For example, the Caco2 cell 
line could be employed to support the observation on IPEC-J2 and improve 
understanding of the mechanism of action of L. reuteri. In addition, 
investigating intestinal immunity in other infection and inflammatory models 
could help to reveal the importance of the targeted genes. The acute colitis 
model could be replaced by a DSS-induced chronic model of colitis with less 
severity, which could help to discriminate between wild type and mutants. 
Therefore, use of a chronic model of colitis is suggested for exploring the 
probiosis mechanism of L. reuteri.
¾ Studies on the possible association between mast cells and beneficial effects 
of L. reuteri revealed inhibition of pro-inflammatory cytokine expression by 
L. reuteri, while IgE antigen-mediated degranulation still occurred. 
Lactobacillus reuteri strains may confer an anti-inflammatory effect through 
inhibition of production and release of mast cell cytokines (IL-13 and IL-6) 
into the extracellular environment, independent of the classical pathway for 
degranulation (Figure 7).  
Lactobacillus reuteri produces lactic acid and lowers the pH, which could 
affect exocytosis and degranulation, an effect which needs to be considered 
in future experiments. 
Lactobacillus reuteri may activate mast cells in a TLR2-dependent manner, 
but this needs further investigation. Future experiments also could be 
designed to study the effect of L. reuteri on factors such as spleen tyrosine 
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kinase (Syk) in signalling cascades which are involved in phosphorylation of 
signalling molecules and subsequent degranulation.  
The study on mast cell-L. reuteri interactions was a pilot study and additional 
experiments need to be conducted in the future. The mechanisms underlying 
differential mediator release in response to L. reuteri are unknown and the 
mechanisms by which L. reuteri influences the mast cell response need to be 
elucidated in upcoming studies. 
There is conclusive evidence for the role of mast cells in the regulation of 
immunity and mucosal integrity of the gut and mast cells possibly could be 
considered as one of the potential mediators of the mechanism of action of 
probiotics.  
Figure 7. Schematic illustration of the possible effects of Lactobacillus reuteri on mast cell 
degranulation and cytokine release. (Left) IgE/antigen-induced degranulation and cytokine
expression and (right) L. reuteri-mediated cytokine downregulation.
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